Browse the corpus

Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.

• 'Equity' and 'Justice' for patients with acute-on chronic liver failure: A call to action.1 passage
• (untitled)1 passage
• 14-3-3η is a novel growth-promoting and angiogenic factor in hepatocellular carcinoma.1 passage
• 24-Norursodeoxycholic acid reshapes immunometabolism in CD81 passage
• 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.1 passage
• A CCRK-EZH2 epigenetic circuitry drives hepatocarcinogenesis and associates with tumor recurrence and poor survival of patients.1 passage
• A cell culture system for distinguishing hepatitis C viruses with and without liver cancer-related mutations in the viral core gene.1 passage
• A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors.1 passage
• A changing landscape of liver transplantation: King HCV is dethroned, ALD and NAFLD take over!1 passage
• A combined model based on spleen stiffness measurement and Baveno VI criteria to rule out high-risk varices in advanced chronic liver disease.1 passage
• A common variant in PNPLA3 is associated with age at diagnosis of NAFLD in patients from a multi-ethnic biobank.1 passage
• A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets.1 passage
• A critical review of endpoints for non-cirrhotic NASH therapeutic trials.1 passage
• A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe.1 passage
• A de novo mutation in KCNN3 associated with autosomal dominant idiopathic non-cirrhotic portal hypertension.1 passage
• A defect in endothelial autophagy occurs in patients with non-alcoholic steatohepatitis and promotes inflammation and fibrosis.1 passage
• A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer.1 passage
• A dual role for hepatocyte-intrinsic canonical NF-κB signaling in virus control.1 passage
• A focus on the role of platelets in liver regeneration: Do platelet-endothelial cell interactions initiate the regenerative process?1 passage
• A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers.1 passage
• A global investment framework for the elimination of hepatitis B.1 passage
• A heterogeneous hierarchy of co-regulatory receptors regulates exhaustion of HCV-specific CD8 T cells in patients with chronic hepatitis C.1 passage
• A heterozygous mutation in GOT1 is associated with familial macro-aspartate aminotransferase.1 passage
• A local response to COVID-19 for advanced liver disease: Current model of care, challenges and opportunities.1 passage
• A model including sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant candidates: A competing risk analysis in a national cohort.1 passage
• A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.1 passage
• A multicentre outcome analysis to define global benchmarks for donation after circulatory death liver transplantation.1 passage
• A multicentre randomized controlled trial of moderate hypothermia to prevent intracranial hypertension in acute liver failure.1 passage
• A new HDV mouse model identifies mitochondrial antiviral signaling protein (MAVS) as a key player in IFN-β induction.1 passage
• A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.1 passage
• A new fluorescence-based optical imaging method to non-invasively monitor hepatic myofibroblasts in vivo.1 passage
• A new formula for calculating standard liver volume for living donor liver transplantation without using body weight.1 passage
• A new perspective on NAFLD: focusing on lipid droplets.1 passage
• A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma.1 passage
• A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement.1 passage
• A novel HBx genotype serves as a preoperative predictor and fails to activate the JAK1/STATs pathway in hepatocellular carcinoma.1 passage
• A novel hepatitis B virus species discovered in capuchin monkeys sheds new light on the evolution of primate hepadnaviruses.1 passage
• A novel microRNA-based prognostic model outperforms standard prognostic models in patients with acetaminophen-induced acute liver failure.1 passage
• A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival.1 passage
• A pilot study of golexanolone, a new GABA-A receptor-modulating steroid antagonist, in patients with covert hepatic encephalopathy.1 passage
• A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY).1 passage
• A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA.1 passage
• A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR.1 passage
• A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.1 passage
• A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection.1 passage
• A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.1 passage
• A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.1 passage
• A schistosome miRNA promotes host hepatic fibrosis by targeting transforming growth factor beta receptor III.1 passage
• A serum protein factor mediates maturation and apoB-association of HCV particles in the extracellular milieu.1 passage
• A simple clinical score to promote and enhance ferroportin disease screening.1 passage
• A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis.1 passage
• A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis.1 passage
• A synthetic biology-based device prevents liver injury in mice.1 passage
• ACOX2 deficiency: An inborn error of bile acid synthesis identified in an adolescent with persistent hypertransaminasemia.1 passage
• ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD.1 passage
• ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma.1 passage
• ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1α.1 passage
• ALDH2 deficiency promotes alcohol-associated liver cancer by activating oncogenic pathways via oxidized DNA-enriched extracellular vesicles.1 passage
• ARID2 modulates DNA damage response in human hepatocellular carcinoma cells.1 passage
• ARRB1 inhibits non-alcoholic steatohepatitis progression by promoting GDF15 maturation.1 passage
• AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.1 passage
• Abbreviated MRI for hepatocellular carcinoma screening: A systematic review and meta-analysis.1 passage
• Abnormal neutrophil traps and impaired efferocytosis contribute to liver injury and sepsis severity after binge alcohol use.1 passage
• Absent in melanoma 2 triggers a heightened inflammasome response in ascitic fluid macrophages of patients with cirrhosis.1 passage
• Access to care in rare liver diseases: New challenges and new opportunities.1 passage
• Accumulation of duct cells with activated YAP parallels fibrosis progression in non-alcoholic fatty liver disease.1 passage
• Acetaminophen (APAP) hepatotoxicity-Isn't it time for APAP to go away?1 passage
• Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.1 passage
• Acetylation of lactate dehydrogenase B drives NAFLD progression by impairing lactate clearance.1 passage
• Acid sphingomyelinase-ceramide system in steatohepatitis: a novel target regulating multiple pathways.1 passage
• Acid-base disorders in liver disease.1 passage
• Activating transcription factor 3 is a target molecule linking hepatic steatosis to impaired glucose homeostasis.1 passage
• Activation and transcriptional profile of monocytes and CD81 passage
• Activation of Slit2-Robo1 signaling promotes liver fibrosis.1 passage
• Activation of YAP attenuates hepatic damage and fibrosis in liver ischemia-reperfusion injury.1 passage
• Activation of biliary tree stem cells within peribiliary glands in primary sclerosing cholangitis.1 passage
• Acute liver failure: A curable disease by 2024?1 passage
• Acute-on-chronic liver failure in patients with alcohol-related liver disease.1 passage
• Acute-on-chronic liver failure: A distinct clinical syndrome.1 passage
• Acute-on-chronic liver failure: A new syndrome that will re-classify cirrhosis.1 passage
• Adaptive immunity in HBV infection.1 passage
• Addressing the next challenges: A summary of the 22nd international symposium on hepatitis C virus and related viruses.1 passage
• Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease.1 passage
• Advanced preclinical models for evaluation of drug-induced liver injury - consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET].1 passage
• Advances in functional and molecular MRI technologies in chronic liver diseases.1 passage
• Advances in molecular classification and precision oncology in hepatocellular carcinoma.1 passage
• Advances in resection and transplantation for hepatocellular carcinoma.1 passage
• Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review.1 passage
• Age and liver transplantation.1 passage
• Age at menarche and non-alcoholic fatty liver disease.1 passage
• Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis.1 passage
• Aiming for cure in HBV and HDV infection.1 passage
• Alcohol and liver disease in Europe--Simple measures have the potential to prevent tens of thousands of premature deaths.1 passage
• Alcohol consumption in late adolescence is associated with an increased risk of severe liver disease later in life.1 passage
• Alcohol directly stimulates epigenetic modifications in hepatic stellate cells.1 passage
• Alcohol drinking pattern and risk of alcoholic liver cirrhosis: a prospective cohort study.1 passage
• Alcohol intake increases the risk of HCC in hepatitis C virus-related compensated cirrhosis: A prospective study.1 passage
• Alcohol stimulates macrophage activation through caspase-dependent hepatocyte derived release of CD40L containing extracellular vesicles.1 passage
• Alcohol-related liver disease: Areas of consensus, unmet needs and opportunities for further study.1 passage
• Aldehyde dedydrogenase-2 plays a beneficial role in ameliorating chronic alcohol-induced hepatic steatosis and inflammation through regulation of autophagy.1 passage
• Alfapump® system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study.1 passage
• Alginate microencapsulated human hepatocytes for the treatment of acute liver failure in children.1 passage
• Allocation of liver grafts worldwide - Is there a best system?1 passage
• Allogeneic haematopoietic stem cell transplantation eliminates alloreactive inhibitory antibodies after liver transplantation for bile salt export pump deficiency.1 passage
• Alpha-1 antitrypsin deficiency: a re-surfacing adult liver disorder.1 passage
• Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation.1 passage
• Alterations of the nuclear transport system in hepatocellular carcinoma - New basis for therapeutic strategies.1 passage
• Altered aryl-hydrocarbon-receptor signalling affects regulatory and effector cell immunity in autoimmune hepatitis.1 passage
• Alternative splicing of hepatitis B virus: A novel virus/host interaction altering liver immunity.1 passage
• Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma.1 passage
• Alternatively activated macrophages promote resolution of necrosis following acute liver injury.1 passage
• Ammonia produces pathological changes in human hepatic stellate cells and is a target for therapy of portal hypertension.1 passage
• An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B.1 passage
• An educate, test and treat model towards elimination of hepatitis C infection in Egypt: Feasibility and effectiveness in 73 villages.1 passage
• An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standards.1 passage
• An integration of deep viral suppression with sequential immune modulation (cocktail therapy) to restore antiviral capacity: the future of chronic hepatitis B?1 passage
• An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs.1 passage
• An international multicenter study of protocols for liver transplantation during a pandemic: A case for quadripartite equipoise.1 passage
• An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers.1 passage
• An ordinal model to predict the risk of symptomatic liver failure in patients with cirrhosis undergoing hepatectomy.1 passage
• An unusual case of acute cholestatic hepatitis after m-RNABNT162b2 (Comirnaty) SARS-CoV-2 vaccine: Coincidence, autoimmunity or drug-related liver injury.1 passage
• Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases.1 passage
• Animal models for liver disease - A practical approach for translational research.1 passage
• Anti-HBV response to toll-like receptor 7 agonist GS-9620 is associated with intrahepatic aggregates of T cells and B cells.1 passage
• Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study.1 passage
• Antibody avidity-based approach to estimate population-level incidence of hepatitis C.1 passage
• Antibody-mediated rejection of the liver allograft: An update and a clinico-pathological perspective.1 passage
• Anticoagulation in chronic liver disease.1 passage
• Antiviral therapy improves survival in patients with HBV infection and intrahepatic cholangiocarcinoma undergoing liver resection.1 passage
• Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: A pilot open-label randomized study.1 passage
• Antiviral therapy in the palliative setting of HCC (BCLC-B and -C).1 passage
• Apoptosis of enterocytes and nitration of junctional complex proteins promote alcohol-induced gut leakiness and liver injury.1 passage
• Applicability and prognostic value of histologic scoring systems in primary sclerosing cholangitis.1 passage
• Application of prognostic scores in the STOPAH trial: Discriminant function is no longer the optimal scoring system in alcoholic hepatitis.1 passage
• Are targeted treatment recommendations in chronic hepatitis C tailored to diagnostic methods of fibrosis?1 passage
• Arid1a regulates response to anti-angiogenic therapy in advanced hepatocellular carcinoma.1 passage
• Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma.1 passage
• Asian perspective on NAFLD-associated HCC.1 passage
• Assembly and infection efficacy of hepatitis B virus surface protein exchanges in 8 hepatitis D virus genotype isolates.1 passage
• Assessing the cost-effectiveness of hepatitis C screening strategies in France.1 passage
• Assessing the role of amino acids in systemic inflammation and organ failure in patients with ACLF.1 passage
• Assessment of response to beta-blockers by expression of βArr2 and RhoA/ROCK2 in antrum mucosa in cirrhotic patients.1 passage
• Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis: An observational cohort study.1 passage
• Association between physical activity and risk of hepatobiliary cancers: A multinational cohort study.1 passage
• Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia.1 passage
• Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A.1 passage
• Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B.1 passage
• Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis.1 passage
• Association of diabetes and PNPLA3 genetic variants with disease severity of patients with chronic hepatitis C virus infection.1 passage
• Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.1 passage
• Association of liver abnormalities with in-hospital mortality in patients with COVID-19.1 passage
• Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients.1 passage
• Associations between reproductive factors and biliary tract cancers in women from the Biliary Tract Cancers Pooling Project.1 passage
• Attacking hepatitis B virus cccDNA--The holy grail to hepatitis B cure.1 passage
• Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: One or even several swallows do not make a summer.1 passage
• Autophagy and senescence in fibrosing cholangiopathies.1 passage
• Autophagy in hepatic adaptation to stress.1 passage
• Autophagy in liver diseases: Time for translation?1 passage
• Autotaxin activity has a high accuracy to diagnose intrahepatic cholestasis of pregnancy.1 passage
• Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication.1 passage
• B cell immunodominance in primary hepatitis C virus infection.1 passage
• BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA.1 passage
• BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update.1 passage
• Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis.1 passage
• Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis.1 passage
• Baseline interpatient hepatitis B viral diversity differentiates HBsAg outcomes in patients treated with tenofovir disoproxil fumarate.1 passage
• Battlefield against hepatitis B infection and HCC in Africa.1 passage
• Baveno VI criteria and spleen stiffness measurement rule out high-risk varices in virally suppressed HBV-related cirrhosis.1 passage
• Benchmark performance of laparoscopic left lateral sectionectomy and right hepatectomy in expert centers.1 passage
• Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease.1 passage
• Benefits of molecular profiling with next-generation sequencing for the diagnosis and prognosis of myeloproliferative neoplasms in splanchnic vein thrombosis.1 passage
• Beta adrenergic blockade and decompensated cirrhosis.1 passage
• Beta-amyloid deposition around hepatic bile ducts is a novel pathobiological and diagnostic feature of biliary atresia.1 passage
• Bi-directional analysis between fatty liver and cardiovascular disease risk factors.1 passage
• Biallelic inactivation of protoporphyrinogen oxidase and hydroxymethylbilane synthase is associated with liver cancer in acute porphyrias.1 passage
• Bifidobacterium pseudocatenulatum CECT7765 induces an M2 anti-inflammatory transition in macrophages from patients with cirrhosis.1 passage
• Biliary atresia and other cholestatic childhood diseases: Advances and future challenges.1 passage
• Biliary bile acids in hepatobiliary injury - What is the link?1 passage
• Biliary epithelium and liver B cells exposed to bacteria activate intrahepatic MAIT cells through MR1.1 passage
• Bilirubin: The yellow hormone?1 passage
• Bioinformatics and database resources in hepatology.1 passage
• Biology of the immunomodulatory molecule HLA-G in human liver diseases.1 passage
• Birth cohort-specific disparities in hepatocellular carcinoma stage at diagnosis, treatment, and long-term survival.1 passage
• Bivalent role of intra-platelet serotonin in liver regeneration and tumor recurrence in humans.1 passage
• Blocking integrin α1 passage
• Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF.1 passage
• Boceprevir, peginterferon and ribavirin for acute hepatitis C in HIV infected patients.1 passage
• Bone marrow-derived and resident liver macrophages display unique transcriptomic signatures but similar biological functions.1 passage
• Breast tumor kinase/protein tyrosine kinase 6 (Brk/PTK6) activity in normal and neoplastic biliary epithelia.1 passage
• Burden of hepatitis E infection and associated healthcare resource utilization among hematological malignancy-related hospitalizations: A national perspective in the United States, 2007-2014.1 passage
• Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies.1 passage
• Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus.1 passage
• Burden of liver diseases in the world.1 passage
• Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019.1 passage
• C19orf66 is an interferon-induced inhibitor of HCV replication that restricts formation of the viral replication organelle.1 passage
• C5aR, TNF-α, and FGL2 contribute to coagulation and complement activation in virus-induced fulminant hepatitis.1 passage
• CAD-LT score effectively predicts risk of significant coronary artery disease in liver transplant candidates.1 passage
• CD147 reprograms fatty acid metabolism in hepatocellular carcinoma cells through Akt/mTOR/SREBP1c and P38/PPARα pathways.1 passage
• CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis.1 passage
• CD4+ CXCR5+ T cells in chronic HCV infection produce less IL-21, yet are efficient at supporting B cell responses.1 passage
• CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma.1 passage
• CD44 is a key player in non-alcoholic steatohepatitis.1 passage
• CMV infection of human sinusoidal endothelium regulates hepatic T cell recruitment and activation.1 passage
• COVID-19 and the liver.1 passage
• COVID-19: Abnormal liver function tests.1 passage
• COVID-19: Discovery, diagnostics and drug development.1 passage
• CXC chemokine receptor 3 promotes steatohepatitis in mice through mediating inflammatory cytokines, macrophages and autophagy.1 passage
• CXCL10/CXCR3 signaling mobilized-regulatory T cells promote liver tumor recurrence after transplantation.1 passage
• CXCL13-mediated recruitment of intrahepatic CXCR51 passage
• CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt.1 passage
• Can NASH lipidome provide insight into the pathogenesis of obesity-related non-alcoholic fatty liver disease?1 passage
• Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma?1 passage
• Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?1 passage
• Canalicular membrane MRP2/ABCC2 internalization is determined by Ezrin Thr567 phosphorylation in human obstructive cholestasis.1 passage
• Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma.1 passage
• Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis.1 passage
• Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites.1 passage
• Caspase recruitment domain 6 protects against hepatic ischemia/reperfusion injury by suppressing ASK1.1 passage
• Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping.1 passage
• Causes of death in people with chronic HBV infection: A population-based cohort study.1 passage
• Cell therapy for advanced liver diseases: Repair or rebuild.1 passage
• Cell therapy for liver disease: From liver transplantation to cell factory.1 passage
• Central obesity is associated with non-cirrhotic portal vein thrombosis.1 passage
• Central role of the β-cell in driving regression of diabetes after liver transplantation in cirrhotic patients.1 passage
• Cerebrospinal fluid metabolomics highlights dysregulation of energy metabolism in overt hepatic encephalopathy.1 passage
• Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD.1 passage
• Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection.1 passage
• Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.1 passage
• Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.1 passage
• Changes in frailty are associated with waitlist mortality in patients with cirrhosis.1 passage
• Changing epidemiology and outcomes of acute kidney injury in hospitalized patients with cirrhosis - a US population-based study.1 passage
• Changing epidemiology, implications, and recommendations for hepatitis C in women of childbearing age and during pregnancy.1 passage
• Changing incidence patterns of hepatocellular carcinoma among age groups in Taiwan.1 passage
• Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.1 passage
• Characterization of novel entecavir resistance mutations.1 passage
• Characterizing bacterial infections in acute-on-chronic liver failure among patients with cirrhosis from nonalcoholic steatohepatitis.1 passage
• CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.1 passage
• Childhood predictors of adult fatty liver. The Cardiovascular Risk in Young Finns Study.1 passage
• Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages.1 passage
• Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies.1 passage
• Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells.1 passage
• Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription.1 passage
• Circular RNA cSMARCA5 inhibits growth and metastasis in hepatocellular carcinoma.1 passage
• Circulating phospholipid profiling identifies portal contribution to NASH signature in obesity.1 passage
• Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2.1 passage
• Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma.1 passage
• Class III obesity is a risk factor for the development of acute-on-chronic liver failure in patients with decompensated cirrhosis.1 passage
• Clathrin switches transforming growth factor-β role to pro-tumorigenic in liver cancer.1 passage
• Cleaved c-FLIP mediates the antiviral effect of TNF-α against hepatitis B virus by dysregulating hepatocyte nuclear factors.1 passage
• Clinical Practice Guidelines of the European Association for the study of the Liver - Advancing methodology but preserving practicability.1 passage
• Clinical and histologic features of adults with alpha-1 antitrypsin deficiency in a non-cirrhotic cohort.1 passage
• Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation.1 passage
• Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure.1 passage
• Clinical implications of basic research in hepatocellular carcinoma.1 passage
• Clinical management of polycystic liver disease.1 passage
• Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.1 passage
• Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.1 passage
• Clinical outcomes of donation after circulatory death liver transplantation in primary sclerosing cholangitis.1 passage
• Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation.1 passage
• Clinical states of cirrhosis and competing risks.1 passage
• Clinical trial watch: reports from the AASLD Liver Meeting®, Boston, November 2014.1 passage
• Clinical usefulness of the ablative margin assessed by magnetic resonance imaging with Gd-EOB-DTPA for radiofrequency ablation of hepatocellular carcinoma.1 passage
• Clinical utility of genomic analysis in adults with idiopathic liver disease.1 passage
• Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.1 passage
• Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens.1 passage
• Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.1 passage
• Co-expression gene network analysis reveals novel regulatory pathways involved in porto-sinusoidal vascular disease.1 passage
• Coffee and herbal tea consumption is associated with lower liver stiffness in the general population: The Rotterdam study.1 passage
• Combination therapy of sofosbuvir and ribavirin fails to clear chronic hepatitis E infection in a multivisceral transplanted patient.1 passage
• Combined hepatocellular-cholangiocarcinoma: An update.1 passage
• Combined locoregional-immunotherapy for liver cancer.1 passage
• Comparative characterization of B cells specific for HBV nucleocapsid and envelope proteins in patients with chronic hepatitis B.1 passage
• Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States.1 passage
• Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population.1 passage
• Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs.1 passage
• Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance.1 passage
• Comparison of no-touch multi-bipolar vs. monopolar radiofrequency ablation for small HCC.1 passage
• Comparison of risk of hepatocellular carcinoma between tenofovir and entecavir: One direction or no direction.1 passage
• Comparison of the accuracy of AASLD and LI-RADS criteria for the non-invasive diagnosis of HCC smaller than 3 cm.1 passage
• Complete removal of the tumor-bearing portal territory decreases local tumor recurrence and improves disease-specific survival of patients with hepatocellular carcinoma.1 passage
• Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma.1 passage
• Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B.1 passage
• Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry.1 passage
• Constitutive androstane receptor (Car)-driven regeneration protects liver from failure following tissue loss.1 passage
• Continuous de novo generation of spatially segregated hepatitis C virus replication organelles revealed by pulse-chase imaging.1 passage
• Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules.1 passage
• Contrast-enhanced ultrasound can guide the therapeutic strategy by improving the detection of colorectal liver metastases.1 passage
• Contributing factors and outcomes of burn-associated cholestasis.1 passage
• Contribution of alcohol use disorders on the burden of chronic hepatitis C in France, 2008-2013: A nationwide retrospective cohort study.1 passage
• Contribution of β-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: Role of severity of liver disease.1 passage
• Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation.1 passage
• Control of temporal activation of hepatitis C virus-induced interferon response by domain 2 of nonstructural protein 5A.1 passage
• Controlled attenuation parameter and alcoholic hepatic steatosis: Diagnostic accuracy and role of alcohol detoxification.1 passage
• Controversies in clinical trials for alcoholic hepatitis.1 passage
• Coordinated development of the mouse extrahepatic bile duct: Implications for neonatal susceptibility to biliary injury.1 passage
• Correction of hyponatraemia improves cognition, quality of life, and brain oedema in cirrhosis.1 passage
• Cost-effectiveness of alcohol use treatments in patients with alcohol-related cirrhosis.1 passage
• Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction.1 passage
• Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections.1 passage
• Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes.1 passage
• Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance.1 passage
• Cross-talk between autophagy and KLF2 determines endothelial cell phenotype and microvascular function in acute liver injury.1 passage
• Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.1 passage
• Crosstalk between type II NKT cells and T cells leads to spontaneous chronic inflammatory liver disease.1 passage
• Curcumin effectively inhibits oncogenic NF-κB signaling and restrains stemness features in liver cancer.1 passage
• Current and innovative emerging therapies for porphyrias with hepatic involvement.1 passage
• Current efforts and trends in the treatment of NASH.1 passage
• Current knowledge and management of portal vein thrombosis in cirrhosis.1 passage
• Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis.1 passage
• Current trials and novel therapeutic targets for alcoholic hepatitis.1 passage
• Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity.1 passage
• Cystic fibrosis-related liver disease: clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies.1 passage
• DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.1 passage
• DKK3 expression in hepatocytes defines susceptibility to liver steatosis and obesity.1 passage
• DNMT1-mediated methylation of BEX1 regulates stemness and tumorigenicity in liver cancer.1 passage
• Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.1 passage
• Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection.1 passage
• Dampened VEPH1 activates mTORC1 signaling by weakening the TSC1/TSC2 association in hepatocellular carcinoma.1 passage
• Danger signals in liver injury and restoration of homeostasis.1 passage
• Dark and bright side of targeting fibroblast growth factor receptor 4 in the liver.1 passage
• Decades after recovery from hepatitis B and HBsAg clearance the CD8+ T cell response against HBV core is nearly undetectable.1 passage
• Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients.1 passage
• Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting.1 passage
• Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.1 passage
• Declining mortality in critically ill patients with cirrhosis in Australia and New Zealand between 2000 and 2015.1 passage
• Decreased Tim-3 expression is associated with functional abnormalities of monocytes in decompensated cirrhosis without overt bacterial infection.1 passage
• Decreased cardiovascular and extrahepatic cancer-related mortality in treated patients with mild HFE hemochromatosis.1 passage
• Defeating EpCAM(+) liver cancer stem cells by targeting chromatin remodeling enzyme CHD4 in human hepatocellular carcinoma.1 passage
• Defining virus-specific CD8+ TCR repertoires for therapeutic regeneration of T cells against chronic hepatitis E.1 passage
• Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury.1 passage
• Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study.1 passage
• Delta hepatitis within the Veterans Affairs medical system in the United States: Prevalence, risk factors, and outcomes.1 passage
• Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models.1 passage
• Deriving the optimal limit of detection for an HCV point-of-care test for viraemic infection: Analysis of a global dataset.1 passage
• Detection and assessment of infectivity of hepatitis E virus in urine.1 passage
• Determinants of fibrosis progression and regression in NASH.1 passage
• Determinants of mortality in patients with cirrhosis and uncontrolled variceal bleeding.1 passage
• Development and prognostic relevance of a histologic grading and staging system for alcohol-related liver disease.1 passage
• Development and validation of a new prognostic score for hepatitis B virus-related acute-on-chronic liver failure.1 passage
• Development of a nomogram to predict outcome after liver resection for hepatocellular carcinoma in Child-Pugh B cirrhosis.1 passage
• Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study.1 passage
• Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.1 passage
• Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B.1 passage
• Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa.1 passage
• Development of chronic kidney disease after acute kidney injury in patients with cirrhosis is common and impairs clinical outcomes.1 passage
• Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: A cohort study.1 passage
• Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C.1 passage
• Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection.1 passage
• Development of the liver: Insights into organ and tissue morphogenesis.1 passage
• Diabetes as a risk factor for hepatic encephalopathy in cirrhosis patients.1 passage
• Diabetes mellitus as a risk factor of hepatocellular carcinoma in patients with chronic hepatitis B on nucleot(s)ide analogues.1 passage
• Diagnosis and management of secondary causes of steatohepatitis.1 passage
• Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma.1 passage
• Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease.1 passage
• Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis.1 passage
• Diagnostic criteria for hepatocellular carcinoma ⩽3 cm with hepatocyte-specific contrast-enhanced magnetic resonance imaging.1 passage
• Diagnostics in hepatitis C: The end of response-guided therapy?1 passage
• Dicoumarol, an NQO1 inhibitor, blocks cccDNA transcription by promoting degradation of HBx.1 passage
• Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.1 passage
• Disease outcomes in a cohort of women in Ireland infected by hepatitis C-contaminated anti-D immunoglobulin during 1970s.1 passage
• Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in non-alcoholic fatty liver disease.1 passage
• Disparities in hepatitis C testing in U.S. veterans born 1945-1965.1 passage
• Disruption of HNF1α binding site causes inherited severe unconjugated hyperbilirubinemia.1 passage
• Disruption of a regulatory loop between DUSP1 and p53 contributes to hepatocellular carcinoma development and progression.1 passage
• Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease.1 passage
• Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma.1 passage
• Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B.1 passage
• Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?1 passage
• Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation?1 passage
• Donor outcomes in anonymous live liver donation.1 passage
• Dopamine receptor D2 antagonization normalizes profibrotic macrophage-endothelial crosstalk in non-alcoholic steatohepatitis.1 passage
• Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis.1 passage
• Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir.1 passage
• Drug-induced liver injury: Interactions between drug properties and host factors.1 passage
• Dual and opposing roles of the androgen receptor in VETC-dependent and invasion-dependent metastasis of hepatocellular carcinoma.1 passage
• Dynamics and predicted drug response of a gene network linking dedifferentiation with beta-catenin dysfunction in hepatocellular carcinoma.1 passage
• Dysregulated miR-124 and miR-200 expression contribute to cholangiocyte proliferation in the cholestatic liver by targeting IL-6/STAT3 signalling.1 passage
• Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin.1 passage
• Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis.1 passage
• Dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease.1 passage
• EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.1 passage
• EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure.1 passage
• EASL Clinical Practice Guideline: Occupational liver diseases.1 passage
• EASL Clinical Practice Guidelines on hepatitis E virus infection.1 passage
• EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update.1 passage
• EASL Clinical Practice Guidelines on nutrition in chronic liver disease.1 passage
• EASL Clinical Practice Guidelines: Drug-induced liver injury.1 passage
• EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis.1 passage
• EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients.1 passage
• EASL recommendations on treatment of hepatitis C: Final update of the series1 passage
• EASL-CLIF criteria outperform NACSELD criteria for diagnosis and prognostication in ACLF.1 passage
• ECT2 regulates the Rho/ERK signalling axis to promote early recurrence in human hepatocellular carcinoma.1 passage
• EDIL3 is a novel regulator of epithelial-mesenchymal transition controlling early recurrence of hepatocellular carcinoma.1 passage
• EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study.1 passage
• ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients.1 passage
• ERAP1 allotypes shape the epitope repertoire of virus-specific CD81 passage
• Early acetaminophen-protein adducts predict hepatotoxicity following overdose (ATOM-5).1 passage
• Early changes in hepatic energy metabolism and lipid content in recent-onset type 1 and 2 diabetes mellitus.1 passage
• Early inhibition of hepatocyte innate responses by hepatitis B virus.1 passage
• Early initiation of antiviral therapy contributes to a rapid and significant loss of serum HBsAg in infantile-onset hepatitis B.1 passage
• Early liver transplantation for acute alcoholic hepatitis: We can't say no.1 passage
• Early liver transplantation for corticosteroid non-responders with acute severe autoimmune hepatitis: The SURFASA score.1 passage
• Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.1 passage
• Early post-transplant survival: Interaction of MELD score and hospitalization status.1 passage
• Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.1 passage
• Effect of aerobic exercise training dose on liver fat and visceral adiposity.1 passage
• Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial.1 passage
• Effect of ethanol on lipid metabolism.1 passage
• Effect of exercise on the development of new fatty liver and the resolution of existing fatty liver.1 passage
• Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C.1 passage
• Effect of sarcopenia on survival in patients with cirrhosis: A systematic review and meta-analysis.1 passage
• Effect of the clinical course of acute-on-chronic liver failure prior to liver transplantation on post-transplant survival.1 passage
• Effect of ventriculo-arterial coupling on transplant outcomes in cirrhotics: Analysis of pressure-volume curve relations.1 passage
• Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.1 passage
• Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma.1 passage
• Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: A United States cohort.1 passage
• Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.1 passage
• Effector CD81 passage
• Effects of amino acid substitutions in hepatitis B virus surface protein on virion secretion, antigenicity, HBsAg and viral DNA.1 passage
• Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease.1 passage
• Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial.1 passage
• Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort.1 passage
• Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial.1 passage
• Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials.1 passage
• Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4.1 passage
• Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B.1 passage
• Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C.1 passage
• Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia.1 passage
• Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.1 passage
• Efficient long-term amplification of hepatitis B virus isolates after infection of slow proliferating HepG2-NTCP cells.1 passage
• Eight millimetre covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding.1 passage
• Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population.1 passage
• Electroencephalogram variability in patients with cirrhosis associates with the presence and severity of hepatic encephalopathy.1 passage
• Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI.1 passage
• Elevated expression of Erbin destabilizes ERα protein and promotes tumorigenesis in hepatocellular carcinoma.1 passage
• Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma.1 passage
• Eliminating hepatitis C within low-income countries - The need to cure genotypes 4, 5, 6.1 passage
• Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses.1 passage
• Emergency TIPS in a Child-Pugh B patient: When does the window of opportunity open and close?1 passage
• Emerging evidence on the role of the Hippo/YAP pathway in liver physiology and cancer.1 passage
• Emerging molecular therapeutic targets for cholangiocarcinoma.1 passage
• Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.1 passage
• Endoplasmic reticulum heat shock protein gp96 maintains liver homeostasis and promotes hepatocellular carcinogenesis.1 passage
• Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease.1 passage
• Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium.1 passage
• Endpoints and patient stratification in clinical trials for alcoholic hepatitis.1 passage
• Endpoints in clinical trials for liver cancer and their value in evidence-based clinical decision making: An unresolved Gordian knot.1 passage
• Enhanced expression of c-myc in hepatocytes promotes initiation and progression of alcoholic liver disease.1 passage
• Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis.1 passage
• Entry of hepatitis B and hepatitis D virus into hepatocytes: Basic insights and clinical implications.1 passage
• EpCAM-regulated intramembrane proteolysis induces a cancer stem cell-like gene signature in hepatitis B virus-infected hepatocytes.1 passage
• Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease.1 passage
• Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients.1 passage
• Epidemiology and natural history of hepatitis C virus infection among children and young people.1 passage
• Epidemiology and risk-stratification of NAFLD-associated HCC.1 passage
• Epidemiology and surveillance for hepatocellular carcinoma: New trends.1 passage
• Epigenetic basis for monocyte dysfunction in patients with severe alcoholic hepatitis.1 passage
• Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications.1 passage
• Epiplakin attenuates experimental mouse liver injury by chaperoning keratin reorganization.1 passage
• Epithelial-mesenchymal transition in cholangiocarcinoma: From clinical evidence to regulatory networks.1 passage
• Epitranscriptomics in liver disease: Basic concepts and therapeutic potential.1 passage
• Essential roles of FoxM1 in Ras-induced liver cancer progression and in cancer cells with stem cell features.1 passage
• Establishing the independence and clinical importance of non-alcoholic fatty liver disease as a risk factor for cardiovascular disease.1 passage
• Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis.1 passage
• Estimation of renal function in patients with liver cirrhosis: Impact of muscle mass and sex.1 passage
• Evaluating the landscape of gene cooperativity with receptor tyrosine kinases in liver tumorigenesis using transposon-mediated mutagenesis.1 passage
• Evaluating the role of transient elastography post chronic hepatitis C treatment to predict hepatocellular carcinoma.1 passage
• Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients.1 passage
• Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.1 passage
• Evaluation of a micro-spectrometer for the real-time assessment of liver graft with mild-to-moderate macrosteatosis: A proof of concept study.1 passage
• Evaluation of the current guidelines for resection of hepatocellular carcinoma using the Appraisal of Guidelines for Research and Evaluation II instrument.1 passage
• Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.1 passage
• Evidence of good prognosis of hepatocellular adenoma in post-menopausal women.1 passage
• Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments.1 passage
• Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals.1 passage
• Evolutionary biology of human hepatitis viruses.1 passage
• Ex vivo liver resection and autotransplantation as alternative to allotransplantation for end-stage hepatic alveolar echinococcosis.1 passage
• Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients.1 passage
• Excess mortality rate associated with hepatitis C virus infection: A community-based cohort study in rural Egypt.1 passage
• Exercise in cirrhosis: Translating evidence and experience to practice.1 passage
• Exome analysis of the evolutionary path of hepatocellular adenoma-carcinoma transition, vascular invasion and brain dissemination.1 passage
• Exosomes in liver pathology.1 passage
• Experimental in vitro and in vivo models for the study of human hepatitis B virus infection.1 passage
• Exploration of skin perfusion in cirrhotic patients with septic shock.1 passage
• Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease.1 passage
• Exposure to environmental contaminants is associated with altered hepatic lipid metabolism in non-alcoholic fatty liver disease.1 passage
• Expression and functionality of Toll- and RIG-like receptors in HepaRG cells.1 passage
• Expression of NKG2D ligands is downregulated by β-catenin signalling and associates with HCC aggressiveness.1 passage
• Extensive testing or focused testing of patients with elevated liver enzymes.1 passage
• External validation of non-invasive predictors of hepatocellular carcinoma in patients with HCV-related advanced chronic liver disease after oral antivirals.1 passage
• Extracellular vesicles as biomarkers in liver diseases: A clinician's point of view.1 passage
• FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma.1 passage
• FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted.1 passage
• FOXA3 induction under endoplasmic reticulum stress contributes to non-alcoholic fatty liver disease.1 passage
• FXR-dependent Rubicon induction impairs autophagy in models of human cholestasis.1 passage
• Factors associated with spontaneous clearance of chronic hepatitis C virus infection.1 passage
• Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy.1 passage
• Falls are common, morbid, and predictable in patients with cirrhosis.1 passage
• Family occurrence of autoimmune hepatitis: A Danish nationwide registry-based cohort study.1 passage
• Fatty liver is an independent predictor of early carotid atherosclerosis.1 passage
• Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice.1 passage
• Fetal cardiac dysfunction in intrahepatic cholestasis of pregnancy is associated with elevated serum bile acid concentrations.1 passage
• FibroGENE: A gene-based model for staging liver fibrosis.1 passage
• Fibroblast growth factor receptor inhibition induces loss of matrix MCL1 and necrosis in cholangiocarcinoma.1 passage
• Fibrogenic signals persist in DAA-treated HCV patients after sustained virological response.1 passage
• Fibrosis and alcohol-related liver disease.1 passage
• Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.1 passage
• First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B.1 passage
• Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation.1 passage
• Freiburg index of post-TIPS survival (FIPS) a valid prognostic score in patients with cirrhosis but also an advisor against TIPS?1 passage
• Freiburg index of post-TIPS survival: The first score for individual prediction and a complementary tool for risk stratification.1 passage
• Fresh frozen plasma transfusion in patients with cirrhosis and coagulopathy: Effect on conventional coagulation tests and thrombomodulin-modified thrombin generation.1 passage
• From immunosuppression to tolerance.1 passage
• From non-A, non-B hepatitis to hepatitis C virus cure.1 passage
• From the Editor's desk...: June 2016.1 passage
• Fructose and sugar: A major mediator of non-alcoholic fatty liver disease.1 passage
• Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial.1 passage
• Full-length 5'RACE identifies all major HBV transcripts in HBV-infected hepatocytes and patient serum.1 passage
• Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants.1 passage
• Functional imaging in liver tumours.1 passage
• Functional reconstitution of HBV-specific CD8 T cells by in vitro polyphenol treatment in chronic hepatitis B.1 passage
• Functional role of CCL5/RANTES for HCC progression during chronic liver disease.1 passage
• Functions of human liver CD691 passage
• Future landscape of hepatitis C research - Basic, translational and clinical perspectives.1 passage
• Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications.1 passage
• Gap junctions in liver disease: Implications for pathogenesis and therapy.1 passage
• Gas6/Axl pathway is activated in chronic liver disease and its targeting reduces fibrosis via hepatic stellate cell inactivation.1 passage
• Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice.1 passage
• Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.1 passage
• Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies.1 passage
• Gene networks and transcription factor motifs defining the differentiation of stem cells into hepatocyte-like cells.1 passage
• Generation of expandable human pluripotent stem cell-derived hepatocyte-like liver organoids.1 passage
• Generation of hepatobiliary organoids from human induced pluripotent stem cells.1 passage
• Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study.1 passage
• Genetic profiling of hepatocellular carcinoma using next-generation sequencing.1 passage
• Genetic studies of abdominal MRI data identify genes regulating hepcidin as major determinants of liver iron concentration.1 passage
• Genetics and epigenetics of NAFLD and NASH: Clinical impact.1 passage
• Genetics of liver disease: From pathophysiology to clinical practice.1 passage
• Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis.1 passage
• Genome-wide association study identifies TF as a significant modifier gene of iron metabolism in HFE hemochromatosis.1 passage
• Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort1 passage
• Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations.1 passage
• Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a risk factor for early recurrence.1 passage
• Genotype correlates with the natural history of severe bile salt export pump deficiency.1 passage
• Geographical variations in incidence, management and survival of hepatocellular carcinoma in a Western country.1 passage
• Germline and somatic DICER1 mutations in familial and sporadic liver tumors.1 passage
• Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.1 passage
• Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.1 passage
• Global burden of acute viral hepatitis and its association with socioeconomic development status, 1990-2019.1 passage
• Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses.1 passage
• Global genotype distribution of hepatitis C viral infection among people who inject drugs.1 passage
• Global impact of the first wave of COVID-19 on liver transplant centers: A multi-society survey (EASL-ESOT/ELITA-ILTS).1 passage
• Global liver disease burdens and research trends: Analysis from a Chinese perspective.1 passage
• Global trends and predictions in hepatocellular carcinoma mortality.1 passage
• Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma.1 passage
• Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.1 passage
• Glutaminolysis-induced mTORC1 activation drives non-alcoholic steatohepatitis progression.1 passage
• Glycolytic activation of monocytes regulates the accumulation and function of neutrophils in human hepatocellular carcinoma.1 passage
• Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.1 passage
• Grand Rounds: Alcoholic Hepatitis.1 passage
• Grand round: Autoimmune hepatitis.1 passage
• Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study).1 passage
• Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent.1 passage
• Growth of hepatocellular adenoma during pregnancy: A prospective study.1 passage
• Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference1 passage
• Gut and liver T-cells of common clonal origin in primary sclerosing cholangitis-inflammatory bowel disease.1 passage
• Gut microbiome in HCC - Mechanisms, diagnosis and therapy.1 passage
• Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells. Implications for hypercoagulability in cirrhosis.1 passage
• Gut-derived systemic inflammation as a driver of depression in chronic liver disease.1 passage
• Gut-liver immunity.1 passage
• Gα1 passage
• HBV inhibits LPS-induced NLRP3 inflammasome activation and IL-1β production via suppressing the NF-κB pathway and ROS production.1 passage
• HBV replication, pathobiology and therapy: Unanswered questions.1 passage
• HBVcircle: A novel tool to investigate hepatitis B virus covalently closed circular DNA.1 passage
• HBcrAg predicts hepatocellular carcinoma development: An analysis using time-dependent receiver operating characteristics.1 passage
• HBeAg-positive chronic hepatitis B patients with prior long-time exposure to nucleos(t)ide analogues: "switch-to" or "add-on" PegIFN alfa, that is the question.1 passage
• HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.1 passage
• HBx relieves chromatin-mediated transcriptional repression of hepatitis B viral cccDNA involving SETDB1 histone methyltransferase.1 passage
• HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease.1 passage
• HCC surveillance after SVR in patients with F3/F4 fibrosis.1 passage
• HCV epidemiology in high-risk groups and the risk of reinfection.1 passage
• HCV epitope, homologous to multiple human protein sequences, induces a regulatory T cell response in infected patients.1 passage
• HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape.1 passage
• HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.1 passage
• HCV modifies EGF signalling and upregulates production of CXCR2 ligands: Role in inflammation and antiviral immune response.1 passage
• HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe.1 passage
• HCV targeting of patients with cirrhosis.1 passage
• HCV-related lymphoproliferative disorders in the direct-acting antiviral era: From mixed cryoglobulinaemia to B-cell lymphoma.1 passage
• HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure.1 passage
• HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis.1 passage
• HEV-positive blood donations represent a relevant infection risk for immunosuppressed recipients.1 passage
• HIF-1α modulates sex-specific Th17/Treg responses during hepatic amoebiasis.1 passage
• HLA-Bw4 80(T) and multiple HLA-Bw4 copies combined with KIR3DL1 associate with spontaneous clearance of HCV infection in people who inject drugs.1 passage
• Haematopoietic cell-derived Jnk1 is crucial for chronic inflammation and carcinogenesis in an experimental model of liver injury.1 passage
• Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B.1 passage
• Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide.1 passage
• Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide: Methodological issues of confounding and prediction models.1 passage
• Hedgehog pathway mediates early acceleration of liver regeneration induced by a novel two-staged hepatectomy in mice.1 passage
• Hedgehog signalling in liver pathophysiology.1 passage
• Hepatic B cell leukemia-3 promotes hepatic steatosis and inflammation through insulin-sensitive metabolic transcription factors.1 passage
• Hepatic PPARα is critical in the metabolic adaptation to sepsis.1 passage
• Hepatic STAMP2 alleviates high fat diet-induced hepatic steatosis and insulin resistance.1 passage
• Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.1 passage
• Hepatic atrophy following preoperative chemotherapy predicts hepatic insufficiency after resection of colorectal liver metastases.1 passage
• Hepatic benefits of HCV cure.1 passage
• Hepatic cell proliferation plays a pivotal role in the prognosis of alcoholic hepatitis.1 passage
• Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease.1 passage
• Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.1 passage
• Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension.1 passage
• Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure.1 passage
• Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy.1 passage
• Hepatic estrogen receptor α improves hepatosteatosis through upregulation of small heterodimer partner.1 passage
• Hepatic fibrosis: Concept to treatment.1 passage
• Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis.1 passage
• Hepatic manifestations of telomere biology disorders.1 passage
• Hepatic oleate regulates liver stress response partially through PGC-1α during high-carbohydrate feeding.1 passage
• Hepatic steatosis and cardiovascular disease outcomes: An analysis of the Framingham Heart Study.1 passage
• Hepatic steatosis in Wilson disease--Role of copper and PNPLA3 mutations.1 passage
• Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis.1 passage
• Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis.1 passage
• Hepatic stellate cell transdifferentiation involves genome-wide remodeling of the DNA methylation landscape.1 passage
• Hepatic venous pressure gradient in the preoperative assessment of patients with resectable hepatocellular carcinoma.1 passage
• Hepatic-targeted RNA interference provides robust and persistent knockdown of alpha-1 antitrypsin levels in ZZ patients.1 passage
• Hepatitis B core-specific memory B cell responses associate with clinical parameters in patients with chronic HBV.1 passage
• Hepatitis B cure: From discovery to regulatory approval.1 passage
• Hepatitis B surface antigen seroclearance: Immune mechanisms, clinical impact, importance for drug development.1 passage
• Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels.1 passage
• Hepatitis B virus induces RNR-R2 expression via DNA damage response activation.1 passage
• Hepatitis B virus-human chimeric transcript HBx-LINE1 promotes hepatic injury via sequestering cellular microRNA-122.1 passage
• Hepatitis B virus-induced modulation of liver macrophage function promotes hepatocyte infection.1 passage
• Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.1 passage
• Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection.1 passage
• Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences.1 passage
• Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis.1 passage
• Hepatitis C reinfection after sustained virological response.1 passage
• Hepatitis C viral proteins perturb metabolic liver zonation.1 passage
• Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.1 passage
• Hepatitis C virus infection and chronic kidney disease: Time for reappraisal.1 passage
• Hepatitis C virus infection increases the risk of developing peripheral arterial disease: a 9-year population-based cohort study.1 passage
• Hepatitis C virus infection inhibits P-body granule formation in human livers.1 passage
• Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort.1 passage
• Hepatitis C virus variants resistant to macrocyclic NS3-4A inhibitors subvert IFN-β induction by efficient MAVS cleavage.1 passage
• Hepatitis C virus-induced NK cell activation causes metzincin-mediated CD16 cleavage and impaired antibody-dependent cytotoxicity.1 passage
• Hepatitis C virus-induced natural killer cell proliferation involves monocyte-derived cells and the OX40/OX40L axis.1 passage
• Hepatitis C virus-mediated Aurora B kinase inhibition modulates inflammatory pathway and viral infectivity.1 passage
• Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions by 2025.1 passage
• Hepatitis D virus replication is sensed by MDA5 and induces IFN-β/λ responses in hepatocytes.1 passage
• Hepatitis Delta co-infection in humanized mice leads to pronounced induction of innate immune responses in comparison to HBV mono-infection.1 passage
• Hepatitis E virus infection and acute non-traumatic neurological injury: A prospective multicentre study.1 passage
• Hepatitis E virus mutations associated with ribavirin treatment failure result in altered viral fitness and ribavirin sensitivity.1 passage
• Hepatitis E virus persists in the ejaculate of chronically infected men.1 passage
• Hepatitis E virus-induced primary cutaneous CD30(+) T cell lymphoproliferative disorder.1 passage
• Hepatitis E virus: Infection beyond the liver?1 passage
• Hepatitis delta genotype 5 is associated with favourable disease outcome and better response to treatment compared to genotype 1.1 passage
• Hepatitis delta-associated mortality in HIV/HBV-coinfected patients.1 passage
• Hepatobiliary MRI as novel selection criteria in liver transplantation for hepatocellular carcinoma.1 passage
• Hepatobiliary transport kinetics of the conjugated bile acid tracer1 passage
• Hepatocellular carcinoma and lifestyles.1 passage
• Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.1 passage
• Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection.1 passage
• Hepatocellular carcinoma in the setting of alcohol-related liver disease.1 passage
• Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B.1 passage
• Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.1 passage
• Hepatocellular carcinoma surveillance after hepatitis C virus eradication: Is liver stiffness measurement more useful than laboratory fibrosis markers?1 passage
• Hepatocellular nodules expressing markers of hepatocellular adenomas in Budd-Chiari syndrome and other rare hepatic vascular disorders.1 passage
• Hepatocyte glutathione S-transferase mu 2 prevents non-alcoholic steatohepatitis by suppressing ASK1 signaling.1 passage
• Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis.1 passage
• Hepatocyte tissue factor contributes to the hypercoagulable state in a mouse model of chronic liver injury.1 passage
• Hepatocyte vitamin D receptor regulates lipid metabolism and mediates experimental diet-induced steatosis.1 passage
• Hepatocyte-derived extracellular vesicles promote endothelial inflammation and atherogenesis via microRNA-1.1 passage
• Hepatocyte-derived macrophage migration inhibitory factor mediates alcohol-induced liver injury in mice and patients.1 passage
• Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis.1 passage
• Hepatocyte-specific suppression of microRNA-221-3p mitigates liver fibrosis.1 passage
• Hepatocytic p62 suppresses ductular reaction and tumorigenesis in mouse livers with mTORC1 activation and defective autophagy.1 passage
• Hepatokines and adipokines in NASH-related hepatocellular carcinoma.1 passage
• Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy.1 passage
• Hepatovirus 3ABC proteases and evolution of mitochondrial antiviral signaling protein (MAVS).1 passage
• Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma.1 passage
• Hic-5 deficiency attenuates the activation of hepatic stellate cells and liver fibrosis through upregulation of Smad7 in mice.1 passage
• High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis.1 passage
• High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.1 passage
• High hepatic and extrahepatic mortality and low treatment uptake in HCV-coinfected persons in the Swiss HIV cohort study between 2001 and 2013.1 passage
• High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia.1 passage
• High incidence of HCV in HIV-negative men who have sex with men using pre-exposure prophylaxis.1 passage
• High rates of 30-day mortality in patients with cirrhosis and COVID-19.1 passage
• High red and processed meat consumption is associated with non-alcoholic fatty liver disease and insulin resistance.1 passage
• High resolution sequencing of hepatitis C virus reveals limited intra-hepatic compartmentalization in end-stage liver disease.1 passage
• High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial.1 passage
• Higher risk of renal disease in chronic hepatitis C patients: Antiviral therapy survival benefit in patients on hemodialysis.1 passage
• Hip fracture risk in patients with alcoholic cirrhosis: A population-based study using English and Danish data.1 passage
• Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease.1 passage
• Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.1 passage
• Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3.1 passage
• Homozygosity for rs738409:G in PNPLA3 is associated with increased mortality following an episode of severe alcoholic hepatitis.1 passage
• Host - hepatitis C viral interactions: The role of genetics.1 passage
• Host conditioning and rejection monitoring in hepatocyte transplantation in humans.1 passage
• Hotair mediates hepatocarcinogenesis through suppressing miRNA-218 expression and activating P14 and P16 signaling.1 passage
• How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach?1 passage
• Hsp72 protects against liver injury via attenuation of hepatocellular death, oxidative stress, and JNK signaling.1 passage
• Human germline hedgehog pathway mutations predispose to fatty liver.1 passage
• Human hepatitis B virus surface and e antigens inhibit major vault protein signaling in interferon induction pathways.1 passage
• Human liver CD81 passage
• Human liver chimeric mice as a new model of chronic hepatitis E virus infection and preclinical drug evaluation.1 passage
• Human liver infiltrating γδ T cells are composed of clonally expanded circulating and tissue-resident populations.1 passage
• Human liver regeneration in advanced cirrhosis is organized by the portal tree.1 passage
• Human stem cell-derived hepatocytes as a model for hepatitis B virus infection, spreading and virus-host interactions.1 passage
• Humanized mice efficiently engrafted with fetal hepatoblasts and syngeneic immune cells develop human monocytes and NK cells.1 passage
• Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.1 passage
• Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?1 passage
• Hypoxia impairs anti-viral activity of natural killer (NK) cells but has little effect on anti-fibrotic NK cell functions in hepatitis C virus infection.1 passage
• Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through Toll-like receptor 9.1 passage
• IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T cell frequency and increases virus-specific T cell responses.1 passage
• IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease.1 passage
• IL-17A secreted from lymphatic endothelial cells promotes tumorigenesis by upregulation of PD-L1 in hepatoma stem cells.1 passage
• IL-17A/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression.1 passage
• IL-2 contributes to cirrhosis-associated immune dysfunction by impairing follicular T helper cells in advanced cirrhosis.1 passage
• IL-33/ST2 pathway regulates neutrophil migration and predicts outcome in patients with severe alcoholic hepatitis.1 passage
• IL-6 pathway in the liver: From physiopathology to therapy.1 passage
• IQGAP2 is a novel interferon-alpha antiviral effector gene acting non-conventionally through the NF-κB pathway.1 passage
• Ideal oral combinations to eradicate HCV: The role of ribavirin.1 passage
• Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV.1 passage
• Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients.1 passage
• Identification of a xenobiotic as a potential environmental trigger in primary biliary cholangitis.1 passage
• Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study.1 passage
• Imagestream detection and characterisation of circulating tumour cells - A liquid biopsy for hepatocellular carcinoma?1 passage
• Immigration and viral hepatitis.1 passage
• Immune and metabolic shifts during neonatal development reprogram liver identity and function.1 passage
• Immune outcomes in the liver: Is CD8 T cell fate determined by the environment?1 passage
• Immunity-related GTPase induces lipophagy to prevent excess hepatic lipid accumulation.1 passage
• Immunogenomic landscape of hepatocellular carcinoma with immune cell stroma and EBV-positive tumor-infiltrating lymphocytes.1 passage
• Immunomodulatory and antioxidant function of albumin stabilises the endothelium and improves survival in a rodent model of chronic liver failure.1 passage
• Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient.1 passage
• Impact of COVID-19 on global HCV elimination efforts.1 passage
• Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry.1 passage
• Impact of MELD 30-allocation policy on liver transplant outcomes in Italy.1 passage
• Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.1 passage
• Impact of alcohol on the progression of HCV-related liver disease: A systematic review and meta-analysis.1 passage
• Impact of cardiac function, refractory ascites and beta blockers on the outcome of patients with cirrhosis listed for liver transplantation.1 passage
• Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.1 passage
• Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C.1 passage
• Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.1 passage
• Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study.1 passage
• Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy.1 passage
• Impact of higher-order heme degradation products on hepatic function and hemodynamics.1 passage
• Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: molecular networks and biological concepts.1 passage
• Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis.1 passage
• Impact of real-time metabolomics in liver transplantation: Graft evaluation and donor-recipient matching.1 passage
• Impaired cerebral microcirculation induced by ammonium chloride in rats is due to cortical adenosine release.1 passage
• Impaired intracellular signaling, myeloperoxidase release and bactericidal activity of neutrophils from patients with alcoholic cirrhosis.1 passage
• Implications of microbiota and bile acid in liver injury and regeneration.1 passage
• Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir.1 passage
• In vivo reduction of hepatitis B virus antigenemia and viremia by antisense oligonucleotides.1 passage
• Inactivation of caspase 8 in liver parenchymal cells confers protection against murine obstructive cholestasis.1 passage
• Incidence and impact of rejection following simultaneous liver-kidney transplantation.1 passage
• Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir.1 passage
• Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance.1 passage
• Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: Relevance for screening strategies.1 passage
• Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR.1 passage
• Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy.1 passage
• Incidence, predictors and outcomes of acute-on-chronic liver failure in outpatients with cirrhosis.1 passage
• Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant.1 passage
• Increased autophagy sustains the survival and pro-tumourigenic effects of neutrophils in human hepatocellular carcinoma.1 passage
• Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006-2010.1 passage
• Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.1 passage
• Increased risk of non-alcoholic fatty liver disease after diagnosis of celiac disease.1 passage
• Increasing prevalence of cirrhosis among U.S. adults aware or unaware of their chronic hepatitis C virus infection.1 passage
• Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.1 passage
• Individual surveillance using model-based hepatocellular carcinoma risk estimates in chronic hepatitis C patients after antiviral treatment.1 passage
• Inequity in organ allocation for patients awaiting liver transplantation: Rationale for uncapping the model for end-stage liver disease.1 passage
• Infant nutrition and maternal obesity influence the risk of non-alcoholic fatty liver disease in adolescents.1 passage
• Inflammatory pathways in alcoholic steatohepatitis.1 passage
• Inflammatory regulation of steroid sulfatase: A novel mechanism to control estrogen homeostasis and inflammation in chronic liver disease.1 passage
• Infliximab-induced liver injury: Clinical phenotypes, autoimmunity and the role of corticosteroid treatment.1 passage
• Informed consent for live liver donors: A qualitative, prospective study.1 passage
• Infusion of mesenchymal stromal cells after deceased liver transplantation: A phase I-II, open-label, clinical study.1 passage
• Inherited non-alcoholic fatty liver disease and dyslipidemia due to monoallelic ABHD5 mutations.1 passage
• Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function.1 passage
• Inhibition of IRAK4 kinase activity improves ethanol-induced liver injury in mice.1 passage
• Inhibition of PU.1 ameliorates metabolic dysfunction and non-alcoholic steatohepatitis.1 passage
• Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease.1 passage
• Innate immune cells in cirrhosis.1 passage
• Insights into contribution of genetic variants towards the susceptibility of MAFLD revealed by the NMR-based lipoprotein profiling.1 passage
• Insights into the diagnosis of hepatocellular carcinomas with hepatobiliary MRI.1 passage
• Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.1 passage
• Integrating HCV testing with HIV programs improves hepatitis C outcomes in people who inject drugs: A cluster-randomized trial.1 passage
• Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma.1 passage
• Integrative molecular characterisation of gallbladder cancer reveals micro-environment-associated subtypes.1 passage
• Integrative molecular profiling of autoreactive CD4 T cells in autoimmune hepatitis.1 passage
• Integrin β1 passage
• Intelligent liver function testing (iLFT): A trial of automated diagnosis and staging of liver disease in primary care.1 passage
• Intensive care management of acute-on-chronic liver failure.1 passage
• Interferon-free therapy of hepatitis C during wait list and post-transplant risk of hepatocellular carcinoma recurrence.1 passage
• Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication.1 passage
• Interferon-γ-dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice.1 passage
• Interleukin-20 exacerbates acute hepatitis and bacterial infection by downregulating IκBζ target genes in hepatocytes.1 passage
• Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice.1 passage
• Intestinal HIF-1α deletion exacerbates alcoholic liver disease by inducing intestinal dysbiosis and barrier dysfunction.1 passage
• Intestinal virome and therapeutic potential of bacteriophages in liver disease.1 passage
• Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial.1 passage
• Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma.1 passage
• Intracellular accumulation of subviral HBsAg particles and diminished Nrf2 activation in HBV genotype G expressing cells lead to an increased ROI level.1 passage
• Intracellular transport and egress of hepatitis B virus.1 passage
• Intraductal papillary neoplasm of the bile duct: Assessment of invasive carcinoma and long-term outcomes using MRI.1 passage
• Intrahepatic CD2061 passage
• Intrahepatic cholestasis of pregnancy and cancer, immune-mediated and cardiovascular diseases: A population-based cohort study.1 passage
• Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B.1 passage
• Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B.1 passage
• Investigating liver stiffness and viscosity for fibrosis, steatosis and activity staging using shear wave elastography.1 passage
• Iron metabolism and related genetic diseases: A cleared land, keeping mysteries.1 passage
• Irradiation stents vs. conventional metal stents for unresectable malignant biliary obstruction: A multicenter trial.1 passage
• Is antenatal screening for hepatitis C virus cost-effective? A decade's experience at a London centre.1 passage
• Is cryptogenic cirrhosis different from NASH cirrhosis?1 passage
• Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured?1 passage
• KLRG1+ natural killer cells exert a novel antifibrotic function in chronic hepatitis B.1 passage
• Karnofsky performance status before and after liver transplantation predicts graft and patient survival.1 passage
• Keratin 23 is a stress-inducible marker of mouse and human ductular reaction in liver disease.1 passage
• Ketoconazole exacerbates mitophagy to induce apoptosis by downregulating cyclooxygenase-2 in hepatocellular carcinoma.1 passage
• Kidney biomarkers in cirrhosis.1 passage
• Lack of arterial hypervascularity at contrast-enhanced ultrasound should not define the priority for diagnostic work-up of nodules <2 cm.1 passage
• Lack of decline in hepatitis C virus incidence among HIV-positive men who have sex with men during 1990-2014.1 passage
• Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts.1 passage
• Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment.1 passage
• Laminin-332 sustains chemoresistance and quiescence as part of the human hepatic cancer stem cell niche.1 passage
• Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer.1 passage
• Laparoscopic versus open liver resection for hepatocellular carcinoma: Case-matched study with propensity score matching.1 passage
• Late hepatitis B and C diagnosis in relation to disease decompensation and hepatocellular carcinoma development.1 passage
• Limb expression 1-like (LIX1L) protein promotes cholestatic liver injury by regulating bile acid metabolism.1 passage
• Limitations of current liver donor allocation systems and the impact of newer indications for liver transplantation.1 passage
• Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival.1 passage
• Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir.1 passage
• Lipocalin 2 drives neutrophilic inflammation in alcoholic liver disease.1 passage
• Lipocalin-2 mediates non-alcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2.1 passage
• Lipotoxicity and the gut-liver axis in NASH pathogenesis.1 passage
• Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation.1 passage
• Liver - master and servant of serum proteome.1 passage
• Liver Bid suppression for treatment of fibrosis associated with non-alcoholic steatohepatitis.1 passage
• Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules.1 passage
• Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma.1 passage
• Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy.1 passage
• Liver resection and transplantation for intrahepatic cholangiocarcinoma.1 passage
• Liver resection for cancer: New developments in prediction, prevention and management of postresectional liver failure.1 passage
• Liver resection for hepatocellular carcinoma in 313 Western patients: tumor biology and underlying liver rather than tumor size drive prognosis.1 passage
• Liver resection for hepatocellular carcinoma in patients with metabolic syndrome: A multicenter matched analysis with HCV-related HCC.1 passage
• Liver sinusoidal endothelial cells: Physiology and role in liver diseases.1 passage
• Liver stiffness measurement in the primary care setting detects high rates of advanced fibrosis and predicts liver-related events in hepatitis C.1 passage
• Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use.1 passage
• Liver transplant center variability in accepting organ offers and its impact on patient survival.1 passage
• Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: Results of the ELITA/EF-CLIF collaborative study (ECLIS).1 passage
• Liver transplantation for secondary liver tumours: The difficult balance between survival and recurrence.1 passage
• Liver transplantation in patients with liver failure related to exertional heatstroke.1 passage
• Liver transplantation in patients with multiple organ failures: Feasibility and outcomes.1 passage
• Liver transplantation in the most severely ill cirrhotic patients: A multicenter study in acute-on-chronic liver failure grade 3.1 passage
• Liver transplantation using hepatitis B core positive grafts with antiviral monotherapy prophylaxis.1 passage
• Liver-derived cell-free nucleic acids in plasma: Biology and applications in liquid biopsies.1 passage
• Liver-related mortality is similar among men and women with cirrhosis.1 passage
• Long non-coding RNA DILC regulates liver cancer stem cells via IL-6/STAT3 axis.1 passage
• Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.1 passage
• Long-term effectiveness of population-wide multifaceted interventions for hepatocellular carcinoma in Taiwan.1 passage
• Long-term growth and bone development in children of HBV-infected mothers with and without fetal exposure to tenofovir disoproxil fumarate.1 passage
• Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.1 passage
• Long-term metabolic correction of Wilson's disease in a murine model by gene therapy.1 passage
• Long-term outcome in PSC patients receiving azathioprine: Does immunosuppression have a positive effect on survival?1 passage
• Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease.1 passage
• Long-term outcomes in patients with decompensated alcohol-related liver disease, steatohepatitis and Maddrey's discriminant function <32.1 passage
• Long-term quality of life after liver donation in the adult to adult living donor liver transplantation cohort study (A2ALL).1 passage
• Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.1 passage
• Long-term sequelae of drug-induced liver injury.1 passage
• Longer lactation duration is associated with decreased prevalence of non-alcoholic fatty liver disease in women.1 passage
• Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib.1 passage
• Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis.1 passage
• Loss of Gsα impairs liver regeneration through a defect in the crosstalk between cAMP and growth factor signaling.1 passage
• Loss of NDRG2 promotes epithelial-mesenchymal transition of gallbladder carcinoma cells through MMP-19-mediated Slug expression.1 passage
• Loss of fibrocystin promotes interleukin-8-dependent proliferation and CTGF production of biliary epithelium.1 passage
• Loss of hepatocyte identity following aberrant YAP activation: A key mechanism in alcoholic hepatitis.1 passage
• Loss of ileum decreases serum fibroblast growth factor 19 in relation to liver inflammation and fibrosis in pediatric onset intestinal failure.1 passage
• Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients.1 passage
• Low specificity of washout to diagnose hepatocellular carcinoma in nodules showing arterial hyperenhancement in patients with Budd-Chiari syndrome.1 passage
• Low subcutaneous adiposity associates with higher mortality in female patients with cirrhosis.1 passage
• Lytic cell death in metabolic liver disease.1 passage
• MDA5 plays a critical role in interferon response during hepatitis C virus infection.1 passage
• MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease.1 passage
• MMP2/MMP9-mediated CD100 shedding is crucial for inducing intrahepatic anti-HBV CD8 T cell responses and HBV clearance.1 passage
• MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice.1 passage
• MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis.1 passage
• MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways.1 passage
• Machine perfusion in liver transplantation as a tool to prevent non-anastomotic biliary strictures: Rationale, current evidence and future directions.1 passage
• Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF).1 passage
• Macrophage heme oxygenase-1-SIRT1-p53 axis regulates sterile inflammation in liver ischemia-reperfusion injury.1 passage
• Macrophage p38α promotes nutritional steatohepatitis through M1 polarization.1 passage
• Macrophage scavenger receptor 1 contributes to pathogenesis of fulminant hepatitis via neutrophil-mediated complement activation.1 passage
• Magnesium accumulation upon cyclin M4 silencing activates microsomal triglyceride transfer protein improving NASH.1 passage
• Magnetic resonance cholangiogram patterns and clinical profiles of ketamine-related cholangiopathy in drug users.1 passage
• Malnutrition-associated liver steatosis and ATP depletion is caused by peroxisomal and mitochondrial dysfunction.1 passage
• Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients.1 passage
• Management of bacterial and fungal infections in cirrhosis: The MDRO challenge.1 passage
• Management of direct-acting antiviral agent failures.1 passage
• Management of the major complications of cirrhosis: Beyond guidelines.1 passage
• Management of the patient with SVR.1 passage
• Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids.1 passage
• Maternal obesity increases the risk and severity of NAFLD in offspring.1 passage
• Maturation of secreted HCV particles by incorporation of secreted ApoE protects from antibodies by enhancing infectivity.1 passage
• Mechanisms of HBV-induced hepatocellular carcinoma.1 passage
• Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis.1 passage
• Membrane-delimited signaling and cytosolic action of MG53 preserve hepatocyte integrity during drug-induced liver injury.1 passage
• Mesenchymal stromal cell therapy for liver diseases.1 passage
• Metabolic adaptation of skeletal muscle to hyperammonemia drives the beneficial effects of l-leucine in cirrhosis.1 passage
• Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.1 passage
• Metabolic interplay between white, beige, brown adipocytes and the liver.1 passage
• Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis.1 passage
• Methionine and S-adenosylmethionine levels are critical regulators of PP2A activity modulating lipophagy during steatosis.1 passage
• Methodological challenges of performing meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments.1 passage
• Mice lacking liver-specific β-catenin develop steatohepatitis and fibrosis after iron overload.1 passage
• MicroRNA-188-5p suppresses tumor cell proliferation and metastasis by directly targeting FGF5 in hepatocellular carcinoma.1 passage
• MicroRNA-199a-5p inhibition enhances the liver repopulation ability of human embryonic stem cell-derived hepatic cells.1 passage
• MicroRNA-206 prevents hepatosteatosis and hyperglycemia by facilitating insulin signaling and impairing lipogenesis.1 passage
• MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma.1 passage
• MicroRNA-378 promotes hepatic inflammation and fibrosis via modulation of the NF-κB-TNFα pathway.1 passage
• Microbiome as a therapeutic target in alcohol-related liver disease.1 passage
• Microbiome therapeutics for hepatic encephalopathy.1 passage
• Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis.1 passage
• Microencapsulated human mesenchymal stem cells decrease liver fibrosis in mice.1 passage
• Microsteatosis may not interact with macrosteatosis in living donor liver transplantation.1 passage
• Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial.1 passage
• Minimal hepatic encephalopathy in children with chronic liver disease: Prevalence, pathogenesis and magnetic resonance-based diagnosis.1 passage
• Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B∗35:02 as a risk factor.1 passage
• Mirtoselect, an anthocyanin-rich bilberry extract, attenuates non-alcoholic steatohepatitis and associated fibrosis in ApoE(∗)3Leiden mice.1 passage
• Mitochondrial dysfunction governs immunometabolism in leukocytes of patients with acute-on-chronic liver failure.1 passage
• Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma.1 passage
• Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.1 passage
• Model for end-stage liver disease-sodium underestimates 90-day mortality risk in patients with acute-on-chronic liver failure.1 passage
• Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe.1 passage
• Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.1 passage
• Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.1 passage
• Modelling the impact of deferring HCV treatment on liver-related complications in HIV coinfected men who have sex with men.1 passage
• Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.1 passage
• Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy.1 passage
• Molecular and histological correlations in liver cancer.1 passage
• Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.1 passage
• Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.1 passage
• Molecular classification of hepatocellular adenoma in clinical practice.1 passage
• Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease.1 passage
• Molecular profiling of subclinical inflammatory lesions in long-term surviving adult liver transplant recipients.1 passage
• Molecular targeted therapies: Ready for "prime time" in biliary tract cancer.1 passage
• Molecular therapies for HCC: Looking outside the box.1 passage
• Monocytes inhibit hepatitis C virus-induced TRAIL expression on CD561 passage
• Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial.1 passage
• Morphophenotypic changes in human multistep hepatocarcinogenesis with translational implications.1 passage
• Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population.1 passage
• Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15.1 passage
• Multi-organ assessment of compensated cirrhosis patients using quantitative magnetic resonance imaging.1 passage
• Multicenter study on recent portal venous system thrombosis associated with cytomegalovirus disease.1 passage
• Multicenter validation of the liver graft assessment following transplantation (L-GrAFT) score for assessment of early allograft dysfunction.1 passage
• Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study.1 passage
• Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe.1 passage
• Multigenerational maternal obesity increases the incidence of HCC in offspring via miR-27a-3p.1 passage
• Multimodal investigation of rat hepatitis E virus antigenicity: Implications for infection, diagnostics, and vaccine efficacy.1 passage
• Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease.1 passage
• Multiparametric magnetic resonance imaging to predict clinical outcomes in patients with chronic liver disease: A cautionary note on a promising technique.1 passage
• Multivariate metabotyping of plasma predicts survival in patients with decompensated cirrhosis.1 passage
• Muscle fat content is strongly associated with NASH: A longitudinal study in patients with morbid obesity.1 passage
• Mutations in DCDC2 (doublecortin domain containing protein 2) in neonatal sclerosing cholangitis.1 passage
• Myeloid ikaros-SIRT1 signaling axis regulates hepatic inflammation and pyroptosis in ischemia-stressed mouse and human liver.1 passage
• NAFLD and liver transplantation: Current burden and expected challenges.1 passage
• NAFLD as a driver of chronic kidney disease.1 passage
• NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - The debate continues.1 passage
• NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options.1 passage
• NAFLD: a multisystem disease.1 passage
• NF-κB/RelA and Nrf2 cooperate to maintain hepatocyte integrity and to prevent development of hepatocellular adenoma.1 passage
• NK-cell responses are biased towards CD16-mediated effector functions in chronic hepatitis B virus infection.1 passage
• NRF2 activates growth factor genes and downstream AKT signaling to induce mouse and human hepatomegaly.1 passage
• NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome.1 passage
• Natural history and treatment of HCV/HIV coinfection: Is it time to change paradigms?1 passage
• Natural history of acute kidney disease in patients with cirrhosis.1 passage
• Natural history of histologically proven alcohol-related liver disease: A systematic review.1 passage
• Natural history of liver adenomatosis: A long-term observational study.1 passage
• Necessity of time series analysis and effects of direct-acting antivirals on HCV patients awaiting liver transplantation.1 passage
• Neuropsychiatric performance in patients with cirrhosis: Who is "normal"?1 passage
• Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis.1 passage
• New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus.1 passage
• New clinical and pathophysiological perspectives defining the trajectory of cirrhosis.1 passage
• New imaging techniques for liver diseases.1 passage
• New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond.1 passage
• New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD.1 passage
• New trends on obesity and NAFLD in Asia.1 passage
• New trials and results in systemic treatment of HCC.1 passage
• New virological tools for screening, diagnosis and monitoring of hepatitis B and C in resource-limited settings.1 passage
• Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.1 passage
• News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document.1 passage
• Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis.1 passage
• Next-generation sequencing: Application of a novel platform to analyze atypical iron disorders.1 passage
• Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis.1 passage
• No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.1 passage
• No-touch multibipolar radiofrequency ablation vs. surgical resection for solitary hepatocellular carcinoma ranging from 2 to 5 cm.1 passage
• Nocturnal hypoxia in obese-related obstructive sleep apnea as a putative trigger of oxidative stress in pediatric NAFLD progression.1 passage
• Nocturnal hypoxia-induced oxidative stress promotes progression of pediatric non-alcoholic fatty liver disease.1 passage
• Non-alcoholic fatty liver disease - A global public health perspective.1 passage
• Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications.1 passage
• Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis.1 passage
• Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality.1 passage
• Non-alcoholic fatty liver disease in pregnancy is associated with adverse maternal and perinatal outcomes.1 passage
• Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets.1 passage
• Non-enhanced magnetic resonance imaging as a surveillance tool for hepatocellular carcinoma: Comparison with ultrasound.1 passage
• Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MRI: risk of HCC recurrence after radiofrequency ablation.1 passage
• Non-invasive alloimmune risk stratification of long-term liver transplant recipients.1 passage
• Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.1 passage
• Non-invasive assessment of portal hypertension using quantitative magnetic resonance imaging.1 passage
• Non-invasive diagnosis and biomarkers in alcohol-related liver disease.1 passage
• Non-invasive evaluation of portal hypertension using ultrasound elastography.1 passage
• Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.1 passage
• Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis.1 passage
• Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals.1 passage
• Non-invasive prediction of oesophageal varices in patients with cirrhosis secondary to non-alcoholic fatty liver disease.1 passage
• Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices.1 passage
• Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.1 passage
• Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis.1 passage
• Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites.1 passage
• Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B.1 passage
• Normothermic regional perfusion vs. super-rapid recovery in controlled donation after circulatory death liver transplantation.1 passage
• Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.1 passage
• Novel classification of non-malignant portal vein thrombosis: A guide to surgical decision-making during liver transplantation.1 passage
• Novel pH-sensitive multifunctional envelope-type nanodevice for siRNA-based treatments for chronic HBV infection.1 passage
• Novel patient-derived preclinical models of liver cancer.1 passage
• Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancer.1 passage
• Novel pre-mRNA splicing of intronically integrated HBV generates oncogenic chimera in hepatocellular carcinoma.1 passage
• Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis.1 passage
• Nucleotide-binding oligomerization domain 1 (NOD1) modulates liver ischemia reperfusion through the expression adhesion molecules.1 passage
• O-GlcNAc transferase promotes fatty liver-associated liver cancer through inducing palmitic acid and activating endoplasmic reticulum stress.1 passage
• O-GlcNAcylation of RACK1 promotes hepatocellular carcinogenesis.1 passage
• O-GlcNAcylation-dependent upregulation of HO1 triggers ammonia-induced oxidative stress and senescence in hepatic encephalopathy.1 passage
• OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.1 passage
• OX40 stimulation and PD-L1 blockade synergistically augment HBV-specific CD4 T cells in patients with HBeAg-negative infection.1 passage
• Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis.1 passage
• Obeticholic acid may increase the risk of gallstone formation in susceptible patients.1 passage
• Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.1 passage
• Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study.1 passage
• Occult hepatitis B infection and hepatocellular carcinoma: Epidemiology, virology, hepatocarcinogenesis and clinical significance.1 passage
• Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.1 passage
• On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites.1 passage
• Optimal management of hepatitis B virus infection - EASL Special Conference.1 passage
• Optimal methods for measuring eligibility for liver transplant in hepatocellular carcinoma patients undergoing transarterial chemoembolization.1 passage
• Optimism for patients with genotype 4 HCV infection: clinical trials with direct-acting antivirals finally available.1 passage
• Optimizing the use of twitter for research dissemination: The "Three Facts and a Story" randomized-controlled trial.1 passage
• Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta.1 passage
• Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras.1 passage
• Outcome and management of HCV/HIV coinfection pre- and post-liver transplantation. A 2015 update.1 passage
• Outcome of ABO-incompatible adult living-donor liver transplantation for patients with hepatocellular carcinoma.1 passage
• Outcome of paediatric portopulmonary hypertension in the modern management era: A case report of 6 patients.1 passage
• Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.1 passage
• Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study.1 passage
• Outcomes following liver transplantation from HCV-seropositive donors to HCV-seronegative recipients.1 passage
• Outcomes in liver transplantation: does sex matter?1 passage
• Outcomes of DCD liver transplantation using organs treated by hypothermic oxygenated perfusion before implantation.1 passage
• Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study.1 passage
• Outcomes of living liver donors are worse than those of matched healthy controls.1 passage
• Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients.1 passage
• Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial.1 passage
• Outcomes of treatment for hepatitis C in prisoners using a nurse-led, statewide model of care.1 passage
• Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: Is it real and how to measure it?1 passage
• Overview of hepatitis B viral replication and genetic variability.1 passage
• Overweight in late adolescence predicts development of severe liver disease later in life: A 39years follow-up study.1 passage
• PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.1 passage
• PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis.1 passage
• PARP1-mediated PPARα poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease.1 passage
• PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolism.1 passage
• PIVKA-II is an independent prognostic factor for overall survival of HCC patients and maybe associated with epithelial-mesenchymal transition.1 passage
• PNPLA3 gene in liver diseases.1 passage
• PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis.1 passage
• PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis.1 passage
• PSMP/MSMP promotes hepatic fibrosis through CCR2 and represents a novel therapeutic target.1 passage
• PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients.1 passage
• Paediatric fatty liver disease (PeFLD): All is not NAFLD - Pathophysiological insights and approach to management.1 passage
• Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease.1 passage
• Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice.1 passage
• Paneth cells promote angiogenesis and regulate portal hypertension in response to microbial signals.1 passage
• Parasites of the liver - epidemiology, diagnosis and clinical management in the European context.1 passage
• Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond the Milan criteria: a randomized controlled trial.1 passage
• Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction.1 passage
• Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis.1 passage
• Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study.1 passage
• Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH).1 passage
• Pediatric CLIF-SOFA score is the best predictor of 28-day mortality in children with decompensated chronic liver disease.1 passage
• PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis.1 passage
• Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B).1 passage
• Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.1 passage
• Peptide SMIM30 promotes HCC development by inducing SRC/YES1 membrane anchoring and MAPK pathway activation.1 passage
• Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations.1 passage
• Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion.1 passage
• Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology.1 passage
• Performance of two simplified HBV treatment criteria (TREAT-B score and WHO guidelines) in Burkina Faso, West Africa.1 passage
• Perioperative blood transfusion does not influence recurrence-free and overall survivals after curative resection for hepatocellular carcinoma: A Propensity Score Matching Analysis.1 passage
• Perioperative omega-3 fatty acids fail to confer protection in liver surgery: Results of a multicentric, double-blind, randomized controlled trial.1 passage
• Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient.1 passage
• Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status.1 passage
• Personalized treatment of patients with very early hepatocellular carcinoma.1 passage
• Pharmacogenomics of drug-induced liver injury (DILI): Molecular biology to clinical applications.1 passage
• Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment.1 passage
• Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C.1 passage
• Pharmacotherapy for NASH: Current and emerging.1 passage
• Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria.1 passage
• Phenotypic and functional analyses show stem cell-derived hepatocyte-like cells better mimic fetal rather than adult hepatocytes.1 passage
• Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer.1 passage
• Physical activity compared to adiposity and risk of liver-related mortality: Results from two prospective, nationwide cohorts.1 passage
• Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: Lessons from the Egyptian experience.1 passage
• Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis.1 passage
• Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma.1 passage
• Pluripotent stem cell-derived bile canaliculi-forming hepatocytes to study genetic liver diseases involving hepatocyte polarity.1 passage
• Polygenic risk score: A promising predictor for hepatocellular carcinoma in the population with non-alcoholic fatty liver disease.1 passage
• Polyploidy control in hepatic health and disease.1 passage
• Poor efficacy of nucleic acid testing in identifying occult HBV infection and consequences for safety of blood supply in Italy.1 passage
• Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs.1 passage
• Portal hypertension in children: High-risk varices, primary prophylaxis and consequences of bleeding.1 passage
• Portopulmonary hypertension in the current era of pulmonary hypertension management.1 passage
• Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma.1 passage
• Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir.1 passage
• Potentially inappropriate liver transplantation in the era of the "sickest first" policy - A search for the upper limits.1 passage
• Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma.1 passage
• Pre-emptive TIPS for acute variceal bleeding in acute-on-chronic liver failure: Is there enough evidence for a routine recommendation?1 passage
• Pre-treatment estimation of future remnant liver function using gadoxetic acid MRI in patients with HCC.1 passage
• Precision medicine in variceal bleeding: Are we there yet?1 passage
• Preclinical models of non-alcoholic fatty liver disease.1 passage
• Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors.1 passage
• Predicting survival after liver transplantation in patients with hepatocellular carcinoma using the LiTES-HCC score.1 passage
• Predicting the risk of post-hepatectomy portal hypertension using a digital twin: A clinical proof of concept.1 passage
• Prediction, identification and progression of histopathological liver disease activity in children with intestinal failure.1 passage
• Pregnancy and liver disease.1 passage
• Pregnancy in idiopathic non-cirrhotic portal hypertension: A multicentric study on maternal and fetal management and outcome.1 passage
• Prenatal acetaminophen induces liver toxicity in dams, reduces fetal liver stem cells, and increases airway inflammation in adult offspring.1 passage
• Preoperative gadoxetic acid-enhanced MRI for predicting microvascular invasion in patients with single hepatocellular carcinoma.1 passage
• Preserved hemostatic status in patients with non-alcoholic fatty liver disease.1 passage
• Prevalence and short-term mortality of acute-on-chronic liver failure: A national cohort study from the USA.1 passage
• Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios.1 passage
• Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease.1 passage
• Prevalence, features and predictive factors of liver nodules in Fontan surgery patients: The VALDIG Fonliver prospective cohort.1 passage
• Prevention of NAFLD-associated HCC: Role of lifestyle and chemoprevention.1 passage
• Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence.1 passage
• Primary biliary cholangitis: A tale of epigenetically-induced secretory failure?1 passage
• Primary prophylaxis of oesophageal variceal bleeding in children by ligation is safe and as efficient as secondary prophylaxis.1 passage
• Primary sclerosing cholangitis - a comprehensive review.1 passage
• Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation.1 passage
• Production of infectious dromedary camel hepatitis E virus by a reverse genetic system: Potential for zoonotic infection.1 passage
• Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation.1 passage
• Prognosis of French COVID-19 patients with chronic liver disease: A national retrospective cohort study for 2020.1 passage
• Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems.1 passage
• Prognosis of patients with chronic hepatitis B in France (2008-2013): A nationwide, observational and hospital-based study.1 passage
• Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.1 passage
• Prognosis of treated severe alcoholic hepatitis in patients with gastrointestinal bleeding.1 passage
• Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.1 passage
• Prognostic impact of surgery and radiofrequency ablation on single nodular HCC ⩽5 cm: Cohort study based on serum HCC markers.1 passage
• Prognostic markers at adolescence in patients requiring liver transplantation for biliary atresia in adulthood.1 passage
• Prognostic nomogram for patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization.1 passage
• Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease.1 passage
• Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia.1 passage
• Prolactin improves hepatic steatosis via CD36 pathway.1 passage
• Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis.1 passage
• Proposal of a novel MELD exception point system for hepatocellular carcinoma based on tumor characteristics and dynamics.1 passage
• Pros and Cons: Usage of organs from donors infected with hepatitis C virus - Revision in the direct-acting antiviral era.1 passage
• Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease.1 passage
• Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.1 passage
• Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation.1 passage
• Protected or not protected, that is the question - First data on COVID-19 vaccine responses in patients with NAFLD and liver transplant recipients.1 passage
• Protective effect of Th22 cells and intrahepatic IL-22 in drug induced hepatocellular injury.1 passage
• Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients.1 passage
• Prothrombotic genetic risk factors are associated with an increased risk of liver fibrosis in the general population: The Rotterdam Study.1 passage
• Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial.1 passage
• Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: a multicenter prospective study.1 passage
• Quality measurement and improvement in liver transplantation.1 passage
• Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection.1 passage
• Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study.1 passage
• Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection.1 passage
• RNA editing mediates the functional switch of COPA in a novel mechanism of hepatocarcinogenesis.1 passage
• RSK2-inactivating mutations potentiate MAPK signaling and support cholesterol metabolism in hepatocellular carcinoma.1 passage
• Radiofrequency ablation vs. surgery for perivascular hepatocellular carcinoma: Propensity score analyses of long-term outcomes.1 passage
• Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinoma.1 passage
• Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma.1 passage
• Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B.1 passage
• Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.1 passage
• Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin.1 passage
• Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival.1 passage
• Rapid clearance of HCV-related splenic marginal zone lymphoma under an interferon-free, NS3/NS4A inhibitor-based treatment. A case report.1 passage
• Rational HCC screening approaches for patients with NAFLD.1 passage
• Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.1 passage
• Real-time US-CT/MR fusion imaging for percutaneous radiofrequency ablation of hepatocellular carcinoma.1 passage
• Real-time shear-wave elastography: applicability, reliability and accuracy for clinically significant portal hypertension.1 passage
• Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis.1 passage
• Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C.1 passage
• Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C.1 passage
• Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.1 passage
• Real-world treatment for chronic hepatitis C infection in Germany: Analyses from drug prescription data, 2010-2015.1 passage
• Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B.1 passage
• Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS.1 passage
• Recipient characteristics and morbidity and mortality after liver transplantation.1 passage
• Reduced incidence of hepatitis C in 9 villages in rural Egypt: Progress towards national elimination goals.1 passage
• Reduced mitochondrial resilience enables non-canonical induction of apoptosis after TNF receptor signaling in virus-infected hepatocytes.1 passage
• Reduced phenotypic expression in genetic hemochromatosis with time: Role of exposure to non-genetic modifiers.1 passage
• Reducing the neglected burden of viral hepatitis in Africa: strategies for a global approach.1 passage
• Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B.1 passage
• Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.1 passage
• Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival.1 passage
• Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease.1 passage
• Regular exercise decreases liver tumors development in hepatocyte-specific PTEN-deficient mice independently of steatosis.1 passage
• Regulation of epithelial injury and bile duct obstruction by NLRP3, IL-1R1 in experimental biliary atresia.1 passage
• Regulatory CD4+ T cells modulate the interaction between NK cells and hepatic stellate cells by acting on either cell type.1 passage
• Regulatory T-cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis.1 passage
• Relationship of sitting time and physical activity with non-alcoholic fatty liver disease.1 passage
• Relationship of vitamin D with insulin resistance and disease severity in non-alcoholic steatohepatitis.1 passage
• Reliability of a single-region sample to evaluate tumor immune microenvironment in hepatocellular carcinoma.1 passage
• Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease.1 passage
• Reply to "Establishing the independence and clinical importance of non-alcoholic fatty liver disease as a risk factor for cardiovascular disease".1 passage
• Reply to "Hepatic venous pressure gradient for preoperative assessment of patients with resectable hepatocellular carcinoma: A comment for moving forward".1 passage
• Reply to: " 'You know my name, but not my story' - Deciding on an accurate nomenclature for faecal microbiota transplantation": Intestinal microbiota transplantation: Naming a new paradigm.1 passage
• Reply to: "A measure of alcohol consumption in late adolescence associated with liver disease after 39 years of follow-up is insufficient to guide alcohol safe limits".1 passage
• Reply to: "Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?"1 passage
• Reply to: "Antiviral therapy improves survival in patients with HBV infection and intrahepatic cholangiocarcinoma undergoing liver resection: Novel concerns".1 passage
• Reply to: "Burden of hepatitis E infection and associated healthcare resource utilization among hematological malignancy-related hospitalizations: A national perspective in the United States, 2007-2014".1 passage
• Reply to: "Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma?"1 passage
• Reply to: "Clinical relevance of dynamic risk assessment for developing hepatocellular carcinoma during prolonged antiviral therapy".1 passage
• Reply to: "Comparison of risk of hepatocellular carcinoma between tenofovir and entecavir: One direction or no direction".1 passage
• Reply to: "Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes".1 passage
• Reply to: "Definition of SPSS: we need to speak the same language": Computer-assisted image processing for better quantification.1 passage
• Reply to: "Diabetes mellitus as a risk factor of hepatocellular carcinoma in patients with chronic hepatitis B on nucleot(s)ide analogues".1 passage
• Reply to: "Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?"1 passage
• Reply to: "Evaluating the role of transient elastography post chronic hepatitis C treatment to predict hepatocellular carcinoma".1 passage
• Reply to: "Extended DAA indications for hepatitis C patients awaiting liver transplantation and further statistical considerations".1 passage
• Reply to: "Freiburg index of post-TIPS survival (FIPS) a valid prognostic score in patients with cirrhosis but also an advisor against TIPS?"1 passage
• Reply to: "Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide: Methodological issues of confounding and prediction models".1 passage
• Reply to: "Hepatocellular carcinoma surveillance after hepatitis C virus eradication: Is liver stiffness measurement more useful than laboratory fibrosis markers?" and "External validation of noninvasive predictors of hepatocellular carcinoma in patients with HCV advanced chronic liver disease after oral antivirals".1 passage
• Reply to: "Histone deacetylase inhibitor for the treatment of hepatocellular carcinoma: Chemoimmunotherapeutic perspective and prospects".1 passage
• Reply to: "In HIV/HCV co-infected patients T regulatory and myeloid derived suppressor cells persist after successful treatment with directly acting antivirals".1 passage
• Reply to: "Individual surveillance using model-based hepatocellular carcinoma risk estimates in chronic hepatitis C patients after antiviral treatment".1 passage
• Reply to: "May sarcopenia and/or hepatic encephalopathy improve the predictivity of model for end-stage liver disease?" and "Has the time come for using MELD-Sarcopenia score?"1 passage
• Reply to: "Multiparametric magnetic resonance imaging to predict clinical outcomes in patients with chronic liver disease: A cautionary note on a promising technique".1 passage
• Reply to: "NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - The debate continues".1 passage
• Reply to: "NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis": Cryptogenic cirrhosis should not be equated with NASH cirrhosis based on UNOS data mining and Bayesian 'doctrine of chances'.1 passage
• Reply to: "NNMT aggravates hepatic steatosis but alleviates liver injury in alcoholic liver disease" and "Two sides of NNMT in alcoholic and non-alcoholic fatty liver development".1 passage
• Reply to: "Non-invasive prediction of oesophageal varices in patients with cirrhosis secondary to non-alcoholic fatty liver disease".1 passage
• Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)".1 passage
• Reply to: "Polygenic risk score: A promising predictor for hepatocellular carcinoma in the population with non-alcoholic fatty liver disease".1 passage
• Reply to: "Pre-emptive TIPS for acute variceal bleeding in acute-on-chronic liver failure: Is there enough evidence for a routine recommendation?": pTIPS for variceal bleeding in ACLF patients: when and why?1 passage
• Reply to: "Real-world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy".1 passage
• Reply to: "Reply to: 'Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries'".1 passage
• Reply to: "Serum HBV pgRNA as a clinical marker for cccDNA activity": Consistent loss of serum HBV RNA might predict the "para-functional cure" of chronic hepatitis B.1 passage
• Reply to: "Serum metabolic signatures in patients with overt hepatic encephalopathy": Metabolic signature for severe cirrhosis with inflammation or hepatic encephalopathy: Do we really face two different entities?1 passage
• Reply to: "Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B".1 passage
• Reply to: "Sofosbuvir/velpatasvir for patients with chronic genotype 3 HCV infection with compensated cirrhosis: Response to EASL recommendations on treatment of Hepatitis C 2018": EASL Recommendations on Treatment of Hepatitis C 2018: Precision on the treatment of patients with genotype 3a infection and compensated cirrhosis.1 passage
• Reply to: "Stereotactic body radiation therapy vs. radiofrequency ablation for HCC: More questions than answers".1 passage
• Reply to: "The long-term prognosis of alcoholic hepatitis is poor and independent of disease severity for patients surviving an acute episode".1 passage
• Reply to: "The role of the model for end-stage liver disease sodium score and joint models for 90-day mortality prediction in in patients with acute-on-chronic liver failure".1 passage
• Reply to: "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules - A response".1 passage
• Reply to: "Treatment for solitary hepatocellular carcinoma ranging from 2 and 5 cm: Is the curative effect of no-touch multibipolar radiofrequency ablation comparable to that of surgical resection?"1 passage
• Reply to: "Underestimation of portal pressures by wedge hepatic venous pressures in patients with non-alcoholic steatohepatitis related cirrhosis- Possibilities and implications".1 passage
• Reply to: "Validation of response to yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion".1 passage
• Reply to: 'High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients'.1 passage
• Reply to: 'Letter regarding "Benchmark performance of laparoscopic left lateral sectionectomy and right hepatectomy in expert centers"'.1 passage
• Reply to: 'No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease'.1 passage
• Reply to: 'Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis'.1 passage
• Reply to: Correspondence on "A new definition for metabolic associated fatty liver disease: an international expert consensus statement": MAFLD: Moving from a concept to practice.1 passage
• Reply to: Correspondence on "Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival".1 passage
• Reply to: Correspondence relating to "SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19".1 passage
• Reply to: Correspondence relating to the manuscript "Early initiation of antiviral therapy contributes to a rapid and significant loss of serum HBsAg in infantile-onset hepatitis B".1 passage
• Reply to: correspondence regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement": Bringing evidence to the NAFLD-MAFLD debate.1 passage
• Reply to: correspondence regarding "Multicenter validation of the liver graft assessment following transplantation (L-GrAFT) score for assessment of early allograft dysfunction".1 passage
• Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD.1 passage
• Reports from the International Liver Cancer Association (ILCA) congress 2014.1 passage
• Repression of microRNA-130b by thyroid hormone enhances cell motility.1 passage
• Rescue of defective ATP8B1 trafficking by CFTR correctors as a therapeutic strategy for familial intrahepatic cholestasis.1 passage
• Residual risk of HCC during long-term oral nucleos(t)ide analogues (NUCs) in patients with CHB - Is one NUC better than the other?1 passage
• Residual risk of liver disease after hepatitis C virus eradication.1 passage
• Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.1 passage
• Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.1 passage
• Resolution of hepatitis E virus infection in CD8+ T cell-depleted rhesus macaques.1 passage
• Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy.1 passage
• Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B: A randomized controlled study.1 passage
• Restoration of T cell function in chronic hepatitis B patients upon treatment with interferon based combination therapy.1 passage
• Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process.1 passage
• Return to sender: Lymphocyte trafficking mechanisms as contributors to primary sclerosing cholangitis.1 passage
• Reversibility of chemotherapy-related liver injury.1 passage
• Reversion of disease manifestations after HCV eradication.1 passage
• Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma.1 passage
• Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial.1 passage
• Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.1 passage
• Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis.1 passage
• Risk factors for recurrent primary sclerosing cholangitis after liver transplantation.1 passage
• Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.1 passage
• Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure.1 passage
• Risk of hepatocellular carcinoma in Danish outpatients with alcohol-related cirrhosis.1 passage
• Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy.1 passage
• Risk of transfusion-transmitted hepatitis E virus infection from pool-tested platelets and plasma.1 passage
• Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis.1 passage
• Role of anti-HBs in functional cure of HBeAg+ chronic hepatitis B patients infected with HBV genotype A.1 passage
• Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis.1 passage
• Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline.1 passage
• Role of epithelial to mesenchymal transition in hepatocellular carcinoma.1 passage
• Role of imaging-based biomarkers in NAFLD: Recent advances in clinical application and future research directions.1 passage
• Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection.1 passage
• Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease.1 passage
• Role of locoregional therapies in the wake of systemic therapy.1 passage
• Role of the IgG4-related cholangitis autoantigen annexin A11 in cholangiocyte protection.1 passage
• Role of the inflammasome in acetaminophen-induced liver injury and acute liver failure.1 passage
• Roles of alcohol consumption in fatty liver: a longitudinal study.1 passage
• Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis.1 passage
• S-Adenosylmethionine increases circulating very-low density lipoprotein clearance in non-alcoholic fatty liver disease.1 passage
• S100A4 promotes liver fibrosis via activation of hepatic stellate cells.1 passage
• SARS-CoV-2 infection in patients with autoimmune hepatitis.1 passage
• SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19.1 passage
• SEBELIPASE ALFA IN CHILDREN AND ADULTS WITH LYSOSOMAL ACID LIPASE DEFICIENCY: FINAL RESULTS OF THE ARISE STUDY.1 passage
• SEC14L2, a lipid-binding protein, regulates HCV replication in culture with inter- and intra-genotype variations.1 passage
• SIRT1 regulates oncogenesis via a mutant p53-dependent pathway in hepatocellular carcinoma.1 passage
• SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma.1 passage
• STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway.1 passage
• STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection.1 passage
• Sab (Sh3bp5) dependence of JNK mediated inhibition of mitochondrial respiration in palmitic acid induced hepatocyte lipotoxicity.1 passage
• Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis.1 passage
• Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.1 passage
• Safety and efficacy of in vitro fertilisation in patients with chronic liver disease and liver transplantation recipients.1 passage
• Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study.1 passage
• Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study.1 passage
• Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis.1 passage
• Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.1 passage
• Safety, complications and outcome of large volume paracentesis with or without albumin therapy in children with severe ascites due to liver disease.1 passage
• Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B.1 passage
• Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry.1 passage
• Salt-inducible Kinase (SIK1) regulates HCC progression and WNT/β-catenin activation.1 passage
• Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008-2011).1 passage
• Sarcopenia and frailty in decompensated cirrhosis.1 passage
• Sarcopenia from mechanism to diagnosis and treatment in liver disease.1 passage
• Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.1 passage
• Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma.1 passage
• Scavenger receptor class B member 1 (SCARB1) variants modulate hepatitis C virus replication cycle and viral load.1 passage
• Screening is associated with a lower risk of hepatocellular carcinoma-related mortality in patients with chronic hepatitis B.1 passage
• Second generation direct-acting antivirals - Do we expect major improvements?1 passage
• Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group.1 passage
• Secondary analysis of large databases for hepatology research.1 passage
• Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy.1 passage
• Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study.1 passage
• Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.1 passage
• Senescence in chronic liver disease: Is the future in aging?1 passage
• Sensitive and non-invasive assessment of hepatocellular iron using a novel room-temperature susceptometer.1 passage
• Sepsis in alcohol-related liver disease.1 passage
• Sequence variations in HCV core-derived epitopes alter binding of KIR2DL3 to HLA-C∗03:04 and modulate NK cell function.1 passage
• Sequencing of FIC1, BSEP and MDR3 in a large cohort of patients with cholestasis revealed a high number of different genetic variants.1 passage
• Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients.1 passage
• Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound.1 passage
• Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents.1 passage
• Severe acute kidney injury associated with non-steroidal anti-inflammatory drugs in cirrhosis: A case-control study.1 passage
• Severe respiratory complex III defect prevents liver adaptation to prolonged fasting.1 passage
• Sex is associated with differences in gut microbial composition and function in hepatic encephalopathy.1 passage
• Short-term hemodynamic effects of β-blockers influence survival of patients with decompensated cirrhosis.1 passage
• Should living donor liver transplantation be an option when deceased donation is not?1 passage
• Should we undertake surveillance for HCC in patients with NAFLD?1 passage
• Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH.1 passage
• Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.2 passages
• Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.1 passage
• Simultaneous splenectomy improves outcomes after adult living donor liver transplantation.1 passage
• Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in ErbB pathway-mutated gallbladder cancer.1 passage
• Single-cell atlas of hepatic T cells reveals expansion of liver-resident naive-like CD41 passage
• Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.1 passage
• Single-cell genomics and spatial transcriptomics: Discovery of novel cell states and cellular interactions in liver physiology and disease biology.1 passage
• Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma.1 passage
• Single-gene association between GATA-2 and autoimmune hepatitis: A novel genetic insight highlighting immunologic pathways to disease.1 passage
• Sinusoidal communication in liver fibrosis and regeneration.1 passage
• Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.1 passage
• Slow decline of hepatitis B burden in general population: Results from a population-based survey and longitudinal follow-up study in Taiwan.1 passage
• Small molecule-mediated reprogramming of human hepatocytes into bipotent progenitor cells.1 passage
• Socio-economic deprivation significantly impacts clinical management and survival in hepatocellular carcinoma.1 passage
• Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience.1 passage
• Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry.1 passage
• Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4.1 passage
• Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection.1 passage
• Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients.1 passage
• Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.1 passage
• Sofosbuvir/velpatasvir for patients with chronic genotype 3 HCV infection with compensated cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018.1 passage
• Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial.1 passage
• Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion.1 passage
• Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma.1 passage
• Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.1 passage
• Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors.1 passage
• Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.1 passage
• Soraphen A: A broad-spectrum antiviral natural product with potent anti-hepatitis C virus activity.1 passage
• Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma.1 passage
• Stage-specific regulation of the WNT/β-catenin pathway enhances differentiation of hESCs into hepatocytes.1 passage
• Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum.1 passage
• Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis.1 passage
• Statin use and non-alcoholic steatohepatitis in at risk individuals.1 passage
• Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection.1 passage
• Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study.1 passage
• Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C.1 passage
• Statins: Old drugs as new therapy for liver diseases?1 passage
• Stearoyl-CoA desaturase regulates sorafenib resistance via modulation of ER stress-induced differentiation.1 passage
• Stem cell-derived hepatocytes: A novel model for hepatitis E virus replication.1 passage
• Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma.1 passage
• Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis.1 passage
• Stool microbiota are superior to saliva in distinguishing cirrhosis and hepatic encephalopathy using machine learning.1 passage
• Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs.1 passage
• Streamlining radioembolization in UNOS T1/T2 hepatocellular carcinoma by eliminating lung shunt estimation.1 passage
• Strengthening vaccine confidence during the COVID-19 pandemic: A new opportunity for global hepatitis B virus elimination.1 passage
• Structural and functional hepatocyte polarity and liver disease.1 passage
• Submassive hepatic necrosis distinguishes HBV-associated acute on chronic liver failure from cirrhotic patients with acute decompensation.1 passage
• Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C.1 passage
• Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials.1 passage
• Substantial gaps in evaluation and treatment of patients with hepatitis B in the US.1 passage
• Sugar-sweetened beverage, diet soda, and fatty liver disease in the Framingham Heart Study cohorts.1 passage
• Supportive and palliative care in people with cirrhosis: International systematic review of the perspective of patients, family members and health professionals.1 passage
• Surveillance for hepatocellular carcinoma is associated with increased survival: Results from a large cohort in the Netherlands.1 passage
• Surveillance of patients with cirrhosis remains suboptimal in the United States.1 passage
• Survival advantage for patients accepting the offer of a circulatory death liver transplant.1 passage
• Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion.1 passage
• Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study.1 passage
• Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population.1 passage
• Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B.1 passage
• Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.1 passage
• Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.1 passage
• Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension.1 passage
• Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations.1 passage
• Syntenin regulates hepatitis C virus sensitivity to neutralizing antibody by promoting E2 secretion through exosomes.1 passage
• Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb41 passage
• Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality.1 passage
• Systemic therapies for intrahepatic cholangiocarcinoma.1 passage
• Systemic treatment of HCC in special populations.1 passage
• Systemic treatment of hepatocellular carcinoma: An EASL position paper.1 passage
• T cell immunity to hepatitis C virus: Lessons for a prophylactic vaccine.1 passage
• T cell receptor repertoires within liver allografts are different to those in the peripheral blood.1 passage
• T cells and monocyte-derived myeloid cells mediate immunotherapy-related hepatitis in a mouse model.1 passage
• T cells protect against hepatitis A virus infection and limit infection-induced liver injury.1 passage
• T-cell engager antibodies enable T cells to control HBV infection and to target HBsAg-positive hepatoma in mice.1 passage
• TAZ is indispensable for c-MYC-induced hepatocarcinogenesis.1 passage
• TGF-β1-driven reduction of cytoglobin leads to oxidative DNA damage in stellate cells during non-alcoholic steatohepatitis.1 passage
• TLR9 signalling in HCV-associated atypical memory B cells triggers Th1 and rheumatoid factor autoantibody responses.1 passage
• TNF-α/IFN-γ profile of HBV-specific CD4 T cells is associated with liver damage and viral clearance in chronic HBV infection.1 passage
• TOX promotes the exhaustion of antitumor CD81 passage
• TRIM24 suppresses development of spontaneous hepatic lipid accumulation and hepatocellular carcinoma in mice.1 passage
• TTC39B destabilizes retinoblastoma protein promoting hepatic lipogenesis in a sex-specific fashion.1 passage
• TWEAK/Fn14 signalling promotes cholangiocarcinoma niche formation and progression.1 passage
• Targeted lipidomics reveals extensive changes in circulating lipid mediators in patients with acutely decompensated cirrhosis.1 passage
• Targeted-bisulfite sequence analysis of the methylation of CpG islands in genes encoding PNPLA3, SAMM50, and PARVB of patients with non-alcoholic fatty liver disease.1 passage
• Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.1 passage
• Targeting Nestin1 passage
• Targeting TRAF3 signaling protects against hepatic ischemia/reperfusions injury.1 passage
• Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models.1 passage
• Targeting cyclin dependent kinase 5 in hepatocellular carcinoma--A novel therapeutic approach.1 passage
• Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis.1 passage
• Targeting hepatic macrophages to treat liver diseases.1 passage
• Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.1 passage
• Targeting the gut-liver axis in liver disease.1 passage
• Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy.1 passage
• Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target.1 passage
• Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study.1 passage
• Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: A randomised controlled trial.1 passage
• Th17 cell frequency is associated with low bone mass in primary sclerosing cholangitis.1 passage
• The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma.1 passage
• The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure.1 passage
• The COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care.1 passage
• The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease.1 passage
• The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease.1 passage
• The EASL International Liver Foundation: A growing pup with missions that are distinct yet integrated with those of its mother.1 passage
• The Hippo pathway effector YAP controls mouse hepatic stellate cell activation.1 passage
• The PNPLA3 SNP rs738409:G allele is associated with increased liver disease-associated mortality but reduced overall mortality in a population-based cohort.1 passage
• The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology.1 passage
• The UK DCD Risk Score: A new proposal to define futility in donation-after-circulatory-death liver transplantation.1 passage
• The WHO guidelines for chronic hepatitis B fail to detect half of the patients in need of treatment in Ethiopia.1 passage
• The addition of a protease inhibitor increases the risk of infections in patients with hepatitis C-related cirrhosis.1 passage
• The association of liver enzymes with biomarkers of subclinical myocardial damage and structural heart disease.1 passage
• The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content.1 passage
• The bidirectional impacts of alcohol consumption and the metabolic syndrome: Cofactors for progressive fatty liver disease.1 passage
• The burden of hepatitis E among patients with haematological malignancies: A retrospective European cohort study.1 passage
• The challenges of multi-drug-resistance in hepatology.1 passage
• The chances of hepatic resection curing hepatocellular carcinoma.1 passage
• The changing context of hepatitis D.1 passage
• The chaperone dynein LL1 mediates cytoplasmic transport of empty and mature hepatitis B virus capsids.1 passage
• The circadian clock and liver function in health and disease.1 passage
• The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study.1 passage
• The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.1 passage
• The cyclophilin-inhibitor alisporivir stimulates antigen presentation thereby promoting antigen-specific CD8(+) T cell activation.1 passage
• The degree of hepatic steatosis associates with impaired cardiac and autonomic function.1 passage
• The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition.1 passage
• The epigenetic regulator SIRT6 protects the liver from alcohol-induced tissue injury by reducing oxidative stress in mice.1 passage
• The genetics of alcohol dependence and alcohol-related liver disease.1 passage
• The global burden of cirrhosis: A review of disability-adjusted life-years lost and unmet needs.1 passage
• The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.1 passage
• The global prevalence and genetic spectrum of lysosomal acid lipase deficiency: A rare condition that mimics NAFLD.1 passage
• The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis.1 passage
• The gut-liver axis in liver disease: Pathophysiological basis for therapy.1 passage
• The hepatitis delta virus: Replication and pathogenesis.1 passage
• The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control.1 passage
• The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications.1 passage
• The immunophenotype of antigen presenting cells of the mononuclear phagocyte system in normal human liver--a systematic review.1 passage
• The importance of liver functional reserve in the non-surgical treatment of Hepatocellular Carcinoma.1 passage
• The importance of resistance to direct antiviral drugs in HCV infection in clinical practice.1 passage
• The intensive care unit course and outcome in acute-on-chronic liver failure are comparable to other populations.1 passage
• The landscape of gene mutations in cirrhosis and hepatocellular carcinoma.1 passage
• The long non-coding RNA LncHDAC2 drives the self-renewal of liver cancer stem cells via activation of Hedgehog signaling.1 passage
• The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study.1 passage
• The management of childhood liver diseases in adulthood.1 passage
• The metabolic gene HAO2 is downregulated in hepatocellular carcinoma and predicts metastasis and poor survival.1 passage
• The microRNA-449 family inhibits TGF-β-mediated liver cancer cell migration by targeting SOX4.1 passage
• The microbiota in cirrhosis and its role in hepatic decompensation.1 passage
• The molecular functions of hepatocyte nuclear factors - In and beyond the liver.1 passage
• The multifaceted role of cathepsins in liver disease.1 passage
• The multifactorial mechanisms of bacterial infection in decompensated cirrhosis.1 passage
• The non-transcriptional activity of IRF3 modulates hepatic immune cell populations in acute-on-chronic ethanol administration in mice.1 passage
• The nutritional geometry of liver disease including non-alcoholic fatty liver disease.1 passage
• The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection.1 passage
• The orphan nuclear receptor COUP-TFII coordinates hypoxia-independent proangiogenic responses in hepatic stellate cells.1 passage
• The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling.1 passage
• The phosphatidylethanolamine biosynthesis pathway provides a new target for cancer chemotherapy.1 passage
• The potential of induced pluripotent stem cell derived hepatocytes.1 passage
• The progenitor cell dilemma: Cellular and functional heterogeneity in assistance or escalation of liver injury.1 passage
• The prognostic role of hepatic venous pressure gradient in cirrhotic patients undergoing elective extrahepatic surgery.1 passage
• The prognostic value of acute-on-chronic liver failure during the course of severe alcoholic hepatitis.1 passage
• The psychomotor vigilance task: Role in the diagnosis of hepatic encephalopathy and relationship with driving ability.1 passage
• The removal of DAA restrictions in Europe - One step closer to eliminating HCV as a major public health threat.1 passage
• The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: Role of the treatment regimen.1 passage
• The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - A longitudinal cohort study.1 passage
• The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafine.1 passage
• The role of innate immunity in the immunopathology and treatment of HBV infection.1 passage
• The role of molecular enrichment on future therapies in hepatocellular carcinoma.1 passage
• The role of quantitative hepatitis B surface antigen revisited.1 passage
• The role of the model for end-stage liver disease-sodium score and joint models for 90-day mortality prediction in patients with acute-on-chronic liver failure.1 passage
• The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery.1 passage
• The spliceosome factor SART1 exerts its anti-HCV action through mRNA splicing.1 passage
• The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis.1 passage
• The times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analogue therapy.1 passage
• The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy.1 passage
• The trends in incidence of primary liver cancer caused by specific etiologies: Results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention.1 passage
• The yin and yang of evasion and immune activation in HCC.1 passage
• Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model.1 passage
• Therapeutic drug monitoring for sofosbuvir and daclatasvir in transplant recipients with chronic hepatitis C and advanced renal disease.1 passage
• Therapeutic editing of hepatocyte genome in vivo.1 passage
• Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma.1 passage
• Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming.1 passage
• Thyroid-stimulating hormone regulates hepatic bile acid homeostasis via SREBP-2/HNF-4α/CYP7A1 axis.1 passage
• Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules - A response.1 passage
• Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules.1 passage
• Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based study.1 passage
• Time trends of chronic HBV infection over prior decades - A global analysis.1 passage
• Tissue engineering of the biliary tract and modelling of cholestatic disorders.1 passage
• Toll-like receptor 3 downregulation is an escape mechanism from apoptosis during hepatocarcinogenesis.1 passage
• Toll-like receptor 4 is a therapeutic target for prevention and treatment of liver failure.1 passage
• Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism.1 passage
• Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis.1 passage
• Towards a new definition of decompensated cirrhosis.1 passage
• Towards personalised medicine in autoimmune hepatitis: Measurement of thiopurine metabolites results in higher biochemical response rates.1 passage
• Transarterial chemoembolization: modalities, indication, and patient selection.1 passage
• Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia.1 passage
• Transient elastography in autoimmune hepatitis: Timing determines the impact of inflammation and fibrosis.1 passage
• Transition to HBeAg-negative chronic hepatitis B virus infection is associated with reduced cccDNA transcriptional activity.1 passage
• Transition to decompensation and acute-on-chronic liver failure: Role of predisposing factors and precipitating events.1 passage
• Translatomic profiling reveals novel self-restricting virus-host interactions during HBV infection.1 passage
• Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada.1 passage
• Transplantation of a human iPSC-derived hepatocyte sheet increases survival in mice with acute liver failure.1 passage
• Treating alcohol-related liver disease from a public health perspective.1 passage
• Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy.1 passage
• Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial.1 passage
• Treatment failure with DAA therapy: Importance of resistance.1 passage
• Treatment for solitary hepatocellular carcinoma ranging from 2 and 5 cm: Is the curative effect of no-touch multibipolar radiofrequency ablation comparable to that of surgical resection?1 passage
• Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: An ERCHIVES study.1 passage
• Treatment of NAFLD with diet, physical activity and exercise.1 passage
• Treatment of alcohol use disorders in patients with alcoholic liver disease.1 passage
• Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study.1 passage
• Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure.1 passage
• Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.1 passage
• Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000-2014).1 passage
• Trends in mortality after diagnosis of hepatitis C virus infection: an international comparison and implications for monitoring the population impact of treatment.1 passage
• Trends in the management and burden of alcoholic liver disease.1 passage
• Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma.1 passage
• Tumor necrosis factor receptor-associated factor 5 (Traf5) acts as an essential negative regulator of hepatic steatosis.1 passage
• Tumor-derived adenosine promotes macrophage proliferation in human hepatocellular carcinoma.1 passage
• Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection.1 passage
• Two non-psychoactive cannabinoids reduce intracellular lipid levels and inhibit hepatosteatosis.1 passage
• Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study.1 passage
• Type 2 diabetes and risk of hospital admission or death for chronic liver diseases.1 passage
• Type I interferon signaling in systemic immune cells from patients with alcoholic cirrhosis and its association with outcome.1 passage
• Ubiquitin C-terminal hydrolase 1: A novel functional marker for liver myofibroblasts and a therapeutic target in chronic liver disease.1 passage
• Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load.1 passage
• Ultra-high sensitivity HBsAg assay can diagnose HBV reactivation following rituximab-based therapy in patients with lymphoma.1 passage
• Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis.1 passage
• Underestimation of portal pressures by wedge hepatic venous pressures in patients with non-alcoholic steatohepatitis related cirrhosis- Possibilities and implications.1 passage
• Understanding liver immunology using intravital microscopy.1 passage
• Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis.1 passage
• Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: Issue of the interval between HCC treatment and antiviral therapy.1 passage
• Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.1 passage
• Universal screening for alcohol misuse in acute medical admissions is feasible and identifies patients at high risk of liver disease.1 passage
• Unmet clinical need in autoimmune liver diseases.1 passage
• Untargeted lipidomics uncovers lipid signatures that distinguish severe from moderate forms of acutely decompensated cirrhosis.1 passage
• Update of the simplified criteria for autoimmune hepatitis: Evaluation of the methodology for immunoserological testing.1 passage
• Update of the statements on biology and clinical impact of occult hepatitis B virus infection.1 passage
• Update on NAFLD genetics: From new variants to the clinic.1 passage
• Update on alpha-1 antitrypsin deficiency: New therapies.1 passage
• Update on hepatitis E virology: Implications for clinical practice.1 passage
• Upregulation of miR-125b by estrogen protects against non-alcoholic fatty liver in female mice.1 passage
• Urea cycle dysregulation in non-alcoholic fatty liver disease.1 passage
• Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism.1 passage
• Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosis.1 passage
• Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity.1 passage
• Ursodeoxycholic acid in advanced polycystic liver disease: A phase 2 multicenter randomized controlled trial.1 passage
• Ursodeoxycholic acid in pregnancy?1 passage
• Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.1 passage
• Use of the methacetin breath test to classify the risk of cirrhotic complications and mortality in patients evaluated/listed for liver transplantation.1 passage
• Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis.1 passage
• Validating a novel score based on interaction between ACLF grade and MELD score to predict waitlist mortality.1 passage
• Validation of Baveno VI and expanded Baveno VI criteria to identify high-risk varices in patients with MAFLD-related compensated cirrhosis.1 passage
• Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.1 passage
• Validation of the Baveno VI criteria to identify low risk cirrhotic patients not requiring endoscopic surveillance for varices.1 passage
• Validation, clinical utility and limitations of the Amsterdam-Oxford model for primary sclerosing cholangitis.1 passage
• Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter.1 passage
• Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults.1 passage
• Variants in the autophagy-related gene IRGM confer susceptibility to non-alcoholic fatty liver disease by modulating lipophagy.1 passage
• Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients.1 passage
• Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies.1 passage
• Visualization of hepatitis E virus RNA and proteins in the human liver.1 passage
• Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study.1 passage
• Von Willebrand factor delays liver repair after acetaminophen-induced acute liver injury in mice.1 passage
• We need stronger evidence for (or against) hepatocellular carcinoma surveillance.1 passage
• What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C?1 passage
• Who to test and how to test for chronic hepatitis C infection - 2016 WHO testing guidance for low- and middle-income countries.1 passage
• Whole genome sequencing discriminates hepatocellular carcinoma with intrahepatic metastasis from multi-centric tumors.1 passage
• Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: One stone hits two birds.1 passage
• aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis.1 passage
• hiPSC hepatocyte model demonstrates the role of unfolded protein response and inflammatory networks in α1 passage
• mRECIST for HCC: Performance and novel refinements.1 passage
• miR-122--a key factor and therapeutic target in liver disease.1 passage
• miR-1224 inhibits cell proliferation in acute liver failure by targeting the antiapoptotic gene Nfib.1 passage
• miR-34a-dependent overexpression of Per1 decreases cholangiocarcinoma growth.1 passage
• miR-425 regulates inflammatory cytokine production in CD41 passage
• miR-552-3p modulates transcriptional activities of FXR and LXR to ameliorate hepatic glycolipid metabolism disorder.1 passage
• miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.1 passage
• norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.1 passage
• p53 haploinsufficiency and increased mTOR signalling define a subset of aggressive hepatocellular carcinoma.1 passage
• rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis.1 passage
• von Willebrand factor and procoagulant imbalance predict outcome in patients with cirrhosis and thrombocytopenia.1 passage
• β-Klotho gene variation is associated with liver damage in children with NAFLD.1 passage